[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdopePAZZUoF2NMZfe37hvoSRwjzKUZ6zoH3_I2Dmabs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Oslo University Hospital",[4],818,false,193,41,994529,70,620,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Cancer",17,{"name":18,"count":19},"Prostate Cancer",15,{"name":21,"count":22},"Quality of Life",14,{"name":24,"count":25},"Pain",13,{"name":27,"count":28},"Colorectal Cancer",10,{"name":30,"count":31},"Coronary Artery Disease",9,{"name":33,"count":34},"Breast Cancer",8,{"name":36,"count":34},"Atrial Fibrillation",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02608996","Nesiritide in Hypertension","2018-12","Nesiritide",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03314636","Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.","2021-11-01","Carfilzomib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT02546232","Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting","2021-12-31","Carboplatin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03326791","Aspirin in Colorectal Cancer Liver Metastases","2022-02-01","Acetylsalicylic acid",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04423731","Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","2022-10-31","Folfirinox",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT02919787","Nordic Pancreatic Cancer Trial (NorPACT) - 1","2022-12-22","5-FU",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05072262","DSAEK\u002FDMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)","2024-06","Nepafenac Ophthalmic",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05719467","SAINT: Safe Induction of Labor Trial","2025-01-31","Buscopan 20 MG\u002FML Injectable Solution",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT03646357","BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function","2025-04-04","Betablocker",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04898504","HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.","2025-05","Floxuridine",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,154,195,230,252,276,294,321,357,388,425,462,489,507,525,543,569,587,605,633,651,677,695,713,731,778,810,850,881,929,956,974,992,1010,1028,1046,1064,1082,1100,1118,1136,1154,1172,1190,1208,1226,1244,1262,1280,1301,1329,1347,1365,1390,1419,1447,1473,1499,1520,1538,1563,1588,1646,1671,1689,1714,1736,1760,1783,1807,1834,1884,1932,1954,1976,2006,2039,2074,2110,2137,2170,2206,2228,2250,2275,2300,2318,2343,2368,2394,2412,2435,2460,2485,2510,2535,2553,2577,2595,2613,2639,2657,2687,2705,2729,2753,2771,2797,2815,2841,2865,2883,2908,2934,2960,2988,3015,3041,3066,3084,3108,3126,3150,3168,3192,3213,3247,3265,3283,3301,3319,3337,3355,3373,3391,3416,3442,3467,3493,3517,3543,3561,3587,3605,3623,3648,3677,3706,3731,3759,3777,3802,3820,3844,3869,3887,3914,3939,3966,3984,4008,4033,4059,4077,4101,4119,4144,4168,4186,4204,4233,4251,4269,4287,4311,4340,4362,4384,4411,4437,4455,4480,4504,4528,4546,4570,4594,4617,4641,4659,4677,4701,4727,4753,4771,4795,4820,4845,4869,4896,4919,4937,4962,4980,5004,5031,5055,5079,5105,5123,5141,5159,5184,5206,5230,5257,5279,5303,5326,5353,5371,5395,5413,5436,5460,5484,5508,5534,5552,5579,5597,5615,5633,5651,5669,5694,5719,5744,5771,5789,5807,5825,5848,5874,5898,5925,5949,5973,5996,6021,6039,6064,6089,6112,6148,6171,6192,6216,6241,6264,6287,6309,6333,6358,6383,6407,6432,6459,6483],{"intervention":97,"totalTrials":98,"cells":99},"Methotrexate",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":136,"PHASE4":138,"NA":152},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":135,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT05725200","Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","RECRUITING",[91],"2038-12-31","2040-12-31","2022-09-27",40,[117],"Metastatic Colorectal Cancer",[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],"Alectinib","Cetuximab","Crizotinib","Dasatinib","Everolimus","Encorafenib","Gemcitabine","Idelalisib","Larotrectinib","Palbociclib","Panobinostat","Pembrolizumab","Petrozumab","Trastuzumab","Talazoparib","Venetoclax",1,{"trials":137,"activeCount":102},[],{"trials":139,"activeCount":135,"soonestReadout":144},[140],{"nctId":141,"briefTitle":142,"status":110,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT06653634","Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial",[93],"2027-12","2029-12","2024-10-24",150,[149],"Juvenile Idiopathic Arthritis",[97,151],"TNF Inhibitor",{"trials":153,"activeCount":102},[],{"intervention":155,"totalTrials":98,"cells":156},"Ipilimumab",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":178,"PHASE4":180,"NA":193},{"trials":158,"activeCount":102},[],{"trials":160,"activeCount":102},[],{"trials":162,"activeCount":102},[163],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":174},"NCT03409198","Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer","COMPLETED",[91],"2022-05-11","2018-01-21",82,[33,172,173],"Hormone Receptor Positive Tumor","Metastatic Breast Cancer",[155,175,176,177],"Nivolumab","Pegylated liposomal doxorubicin","Cyclophosphamide",{"trials":179,"activeCount":102},[],{"trials":181,"activeCount":135,"soonestReadout":187},[182],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":147,"conditions":190,"interventions":192},"NCT02068196","A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.","ACTIVE_NOT_RECRUITING",[93],"2025-12","2026-12","2014-01",[191],"Malignant Melanoma",[155],{"trials":194,"activeCount":102},[],{"intervention":72,"totalTrials":98,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":228},{"trials":198,"activeCount":102},[],{"trials":200,"activeCount":102},[],{"trials":202,"activeCount":102},[],{"trials":204,"activeCount":102},[],{"trials":206,"activeCount":135,"soonestReadout":71},[207,217],{"nctId":69,"briefTitle":70,"status":110,"phases":208,"primaryCompletion":71,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":215},[93],"2026-10","2022-11-25",300,[213,214],"Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)","Descemet Membrane Endothelial Keratoplasty (DMEK)",[72,216],"Dexamethasone Ophthalmic",{"nctId":218,"briefTitle":219,"status":220,"phases":221,"primaryCompletion":222,"completion":223,"start":210,"enrollment":224,"conditions":225,"interventions":227},"NCT05331690","Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)","UNKNOWN",[93],"2023-08","2023-12",500,[226],"Cataract Surgery",[72,72,216],{"trials":229,"activeCount":102},[],{"intervention":216,"totalTrials":98,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":250},{"trials":233,"activeCount":102},[],{"trials":235,"activeCount":102},[],{"trials":237,"activeCount":102},[],{"trials":239,"activeCount":102},[],{"trials":241,"activeCount":135,"soonestReadout":71},[242,246],{"nctId":69,"briefTitle":70,"status":110,"phases":243,"primaryCompletion":71,"completion":209,"start":210,"enrollment":211,"conditions":244,"interventions":245},[93],[213,214],[72,216],{"nctId":218,"briefTitle":219,"status":220,"phases":247,"primaryCompletion":222,"completion":223,"start":210,"enrollment":224,"conditions":248,"interventions":249},[93],[226],[72,72,216],{"trials":251,"activeCount":102},[],{"intervention":82,"totalTrials":135,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":102},[],{"trials":257,"activeCount":102},[],{"trials":259,"activeCount":102},[],{"trials":261,"activeCount":102},[],{"trials":263,"activeCount":135,"soonestReadout":81},[264],{"nctId":79,"briefTitle":80,"status":185,"phases":265,"primaryCompletion":81,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":273},[93],"2035-12-10","2018-10-01",2895,[270,271,272],"Acute Myocardial Infarction","Non-ST Elevation Myocardial Infarction","ST Elevation Myocardial Infarction",[82],{"trials":275,"activeCount":102},[],{"intervention":151,"totalTrials":135,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":292},{"trials":279,"activeCount":102},[],{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"trials":287,"activeCount":135,"soonestReadout":144},[288],{"nctId":141,"briefTitle":142,"status":110,"phases":289,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":290,"interventions":291},[93],[149],[97,151],{"trials":293,"activeCount":102},[],{"intervention":295,"totalTrials":135,"cells":296},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":319},{"trials":298,"activeCount":102},[],{"trials":300,"activeCount":102},[],{"trials":302,"activeCount":102},[],{"trials":304,"activeCount":102},[],{"trials":306,"activeCount":135,"soonestReadout":311},[307],{"nctId":308,"briefTitle":309,"status":110,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":318},"NCT05788276","Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?",[93],"2028-06","2023-05-02",330,[315,316,317],"Kidney Transplant; Complications","Kidney Transplant Failure","Renal Failure",[295],{"trials":320,"activeCount":102},[],{"intervention":57,"totalTrials":98,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":353,"NA":355},{"trials":324,"activeCount":102},[],{"trials":326,"activeCount":102},[],{"trials":328,"activeCount":102},[],{"trials":330,"activeCount":98,"soonestReadout":56},[331,340],{"nctId":54,"briefTitle":55,"status":185,"phases":332,"primaryCompletion":56,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":339},[91,92],"2026-06","2017-12-15",466,[337,27,338],"Colorectal Cancer Liver Metastases","Liver Metastases",[57],{"nctId":341,"briefTitle":342,"status":110,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT05035277","AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation",[92],"2026-11","2021-12-04",360,[348],"Aortic Stenosis",[57,350,351,352],"Apixaban","Rivaroxaban","Edoxaban",{"trials":354,"activeCount":102},[],{"trials":356,"activeCount":102},[],{"intervention":350,"totalTrials":98,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":378,"PHASE4":384,"NA":386},{"trials":360,"activeCount":102},[],{"trials":362,"activeCount":102},[],{"trials":364,"activeCount":135,"soonestReadout":370},[365],{"nctId":366,"briefTitle":367,"status":368,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":377},"NCT06729034","A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation","NOT_YET_RECRUITING",[91],"2030-12-31","2031-12-31","2025-02-01",20,[375,376],"Venous Malformation, Low Flow","Anticoagulants",[350],{"trials":379,"activeCount":135,"soonestReadout":344},[380],{"nctId":341,"briefTitle":342,"status":110,"phases":381,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":382,"interventions":383},[92],[348],[57,350,351,352],{"trials":385,"activeCount":102},[],{"trials":387,"activeCount":102},[],{"intervention":389,"totalTrials":98,"cells":390},"Metoprolol",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":410,"NA":423},{"trials":392,"activeCount":102},[],{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":102},[],{"trials":398,"activeCount":135,"soonestReadout":333},[399],{"nctId":400,"briefTitle":401,"status":110,"phases":402,"primaryCompletion":333,"completion":333,"start":403,"enrollment":404,"conditions":405,"interventions":408},"NCT05631730","Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse",[92],"2023-01-04",50,[406,407],"Mitral Valve Prolapse","Ventricular Arrhythmias and Cardiac Arrest",[409,389],"Flecainide",{"trials":411,"activeCount":102},[412],{"nctId":413,"briefTitle":414,"status":166,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT01157572","Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation",[93],"2014-08","2014-09","2010-08",75,[421],"Aortic Valve Insufficiency",[389],{"trials":424,"activeCount":102},[],{"intervention":67,"totalTrials":98,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":446,"PHASE4":458,"NA":460},{"trials":428,"activeCount":102},[],{"trials":430,"activeCount":102},[],{"trials":432,"activeCount":102},[433],{"nctId":434,"briefTitle":435,"status":166,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT00278694","Oxaliplatin and 5-FU Based Preoperative Chemoradiation",[91],"2016-02","2005-09",109,[441],"Rectal Cancer",[443,444,67,445],"Oxaliplatin","Chemoradiation","Neoadjuvant oxaliplatin",{"trials":447,"activeCount":135,"soonestReadout":66},[448],{"nctId":64,"briefTitle":65,"status":185,"phases":449,"primaryCompletion":66,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},[91,92],"2026-04-30","2016-09",140,[454],"Pancreatic Cancer",[67,456,457,67,456,457],"Oxaliplatine","Irinotecan",{"trials":459,"activeCount":102},[],{"trials":461,"activeCount":102},[],{"intervention":463,"totalTrials":135,"cells":464},"Early treatment of relapse with carfilzomib, dexamethasone, daratumumab",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":485,"NA":487},{"trials":466,"activeCount":102},[],{"trials":468,"activeCount":102},[],{"trials":470,"activeCount":102},[],{"trials":472,"activeCount":135,"soonestReadout":477},[473],{"nctId":474,"briefTitle":475,"status":110,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT04513639","The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study",[91,92],"2031-06-01","2032-06-01","2020-08-27",176,[482],"Multiple Myeloma",[463,484],"Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab",{"trials":486,"activeCount":102},[],{"trials":488,"activeCount":102},[],{"intervention":484,"totalTrials":135,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":503,"NA":505},{"trials":492,"activeCount":102},[],{"trials":494,"activeCount":102},[],{"trials":496,"activeCount":102},[],{"trials":498,"activeCount":135,"soonestReadout":477},[499],{"nctId":474,"briefTitle":475,"status":110,"phases":500,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":501,"interventions":502},[91,92],[482],[463,484],{"trials":504,"activeCount":102},[],{"trials":506,"activeCount":102},[],{"intervention":351,"totalTrials":135,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":521,"NA":523},{"trials":510,"activeCount":102},[],{"trials":512,"activeCount":102},[],{"trials":514,"activeCount":102},[],{"trials":516,"activeCount":135,"soonestReadout":344},[517],{"nctId":341,"briefTitle":342,"status":110,"phases":518,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":519,"interventions":520},[92],[348],[57,350,351,352],{"trials":522,"activeCount":102},[],{"trials":524,"activeCount":102},[],{"intervention":352,"totalTrials":135,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":539,"NA":541},{"trials":528,"activeCount":102},[],{"trials":530,"activeCount":102},[],{"trials":532,"activeCount":102},[],{"trials":534,"activeCount":135,"soonestReadout":344},[535],{"nctId":341,"briefTitle":342,"status":110,"phases":536,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":537,"interventions":538},[92],[348],[57,350,351,352],{"trials":540,"activeCount":102},[],{"trials":542,"activeCount":102},[],{"intervention":77,"totalTrials":135,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":565,"NA":567},{"trials":546,"activeCount":102},[],{"trials":548,"activeCount":102},[],{"trials":550,"activeCount":102},[],{"trials":552,"activeCount":135,"soonestReadout":76},[553],{"nctId":74,"briefTitle":75,"status":110,"phases":554,"primaryCompletion":76,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":562},[92],"2027-12-31","2023-01-03",3000,[559,560,561],"Labor Complication","Induced; Birth","Pregnancy Related",[77,563,564],"Sodium bicarbonate","Nacl 0.9%",{"trials":566,"activeCount":102},[],{"trials":568,"activeCount":102},[],{"intervention":563,"totalTrials":135,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":583,"NA":585},{"trials":572,"activeCount":102},[],{"trials":574,"activeCount":102},[],{"trials":576,"activeCount":102},[],{"trials":578,"activeCount":135,"soonestReadout":76},[579],{"nctId":74,"briefTitle":75,"status":110,"phases":580,"primaryCompletion":76,"completion":555,"start":556,"enrollment":557,"conditions":581,"interventions":582},[92],[559,560,561],[77,563,564],{"trials":584,"activeCount":102},[],{"trials":586,"activeCount":102},[],{"intervention":564,"totalTrials":135,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":601,"NA":603},{"trials":590,"activeCount":102},[],{"trials":592,"activeCount":102},[],{"trials":594,"activeCount":102},[],{"trials":596,"activeCount":135,"soonestReadout":76},[597],{"nctId":74,"briefTitle":75,"status":110,"phases":598,"primaryCompletion":76,"completion":555,"start":556,"enrollment":557,"conditions":599,"interventions":600},[92],[559,560,561],[77,563,564],{"trials":602,"activeCount":102},[],{"trials":604,"activeCount":102},[],{"intervention":606,"totalTrials":135,"cells":607},"CGRP mAbs and onabotulinumtoxin A",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":629,"NA":631},{"trials":609,"activeCount":102},[],{"trials":611,"activeCount":102},[],{"trials":613,"activeCount":102},[],{"trials":615,"activeCount":135,"soonestReadout":620},[616],{"nctId":617,"briefTitle":618,"status":110,"phases":619,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":627},"NCT07040813","The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy",[92],"2029-01-31","2029-04-30","2025-06-06",450,[625,626],"Migraine","Chronic Migraine Headache",[606,628],"CGRP mAbs and placebo",{"trials":630,"activeCount":102},[],{"trials":632,"activeCount":102},[],{"intervention":628,"totalTrials":135,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":102},[],{"trials":638,"activeCount":102},[],{"trials":640,"activeCount":102},[],{"trials":642,"activeCount":135,"soonestReadout":620},[643],{"nctId":617,"briefTitle":618,"status":110,"phases":644,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":645,"interventions":646},[92],[625,626],[606,628],{"trials":648,"activeCount":102},[],{"trials":650,"activeCount":102},[],{"intervention":652,"totalTrials":135,"cells":653},"Dapagliflozin 10 mg",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":673,"NA":675},{"trials":655,"activeCount":102},[],{"trials":657,"activeCount":102},[],{"trials":659,"activeCount":102},[],{"trials":661,"activeCount":135,"soonestReadout":450},[662],{"nctId":663,"briefTitle":664,"status":110,"phases":665,"primaryCompletion":450,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":672},"NCT05321706","DAPAgliflozin for Renal Protection in Heart Transplant Recipients",[92],"2028-05-31","2022-06-08",430,[670,671],"Heart Transplant Failure","Kidney Failure",[652],{"trials":674,"activeCount":102},[],{"trials":676,"activeCount":102},[],{"intervention":456,"totalTrials":135,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":691,"NA":693},{"trials":680,"activeCount":102},[],{"trials":682,"activeCount":102},[],{"trials":684,"activeCount":102},[],{"trials":686,"activeCount":135,"soonestReadout":66},[687],{"nctId":64,"briefTitle":65,"status":185,"phases":688,"primaryCompletion":66,"completion":450,"start":451,"enrollment":452,"conditions":689,"interventions":690},[91,92],[454],[67,456,457,67,456,457],{"trials":692,"activeCount":102},[],{"trials":694,"activeCount":102},[],{"intervention":457,"totalTrials":135,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":709,"NA":711},{"trials":698,"activeCount":102},[],{"trials":700,"activeCount":102},[],{"trials":702,"activeCount":102},[],{"trials":704,"activeCount":135,"soonestReadout":66},[705],{"nctId":64,"briefTitle":65,"status":185,"phases":706,"primaryCompletion":66,"completion":450,"start":451,"enrollment":452,"conditions":707,"interventions":708},[91,92],[454],[67,456,457,67,456,457],{"trials":710,"activeCount":102},[],{"trials":712,"activeCount":102},[],{"intervention":409,"totalTrials":135,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":727,"NA":729},{"trials":716,"activeCount":102},[],{"trials":718,"activeCount":102},[],{"trials":720,"activeCount":102},[],{"trials":722,"activeCount":135,"soonestReadout":333},[723],{"nctId":400,"briefTitle":401,"status":110,"phases":724,"primaryCompletion":333,"completion":333,"start":403,"enrollment":404,"conditions":725,"interventions":726},[92],[406,407],[409,389],{"trials":728,"activeCount":102},[],{"trials":730,"activeCount":102},[],{"intervention":732,"totalTrials":733,"cells":734},"Chemotherapy",3,{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":736,"activeCount":102},[],{"trials":738,"activeCount":102},[],{"trials":740,"activeCount":135,"soonestReadout":745},[741],{"nctId":742,"briefTitle":743,"status":185,"phases":744,"primaryCompletion":745,"completion":113,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT03544736","Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)",[90,91],"2025-12-31","2018-04-26",30,[749],"Esophageal Cancer",[175,732],{"trials":752,"activeCount":102},[],{"trials":754,"activeCount":102},[],{"trials":756,"activeCount":98,"soonestReadout":774},[757,770],{"nctId":758,"briefTitle":759,"status":110,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":769},"NCT06944587","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer",[],"2028-12-31","2024-12-03",400,[765,766,767,768],"Locally Advanced Pancreatic Cancer","Borderline Resectable Pancreatic Cancer","Pancreatectomy","Chemotherapy Effect",[732],{"nctId":771,"briefTitle":772,"status":110,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":747,"conditions":776,"interventions":777},"NCT03494946","Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer",[94],"2027-01","2016-12-05",[338,27],[732],{"intervention":87,"totalTrials":98,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":781,"activeCount":102},[],{"trials":783,"activeCount":102},[],{"trials":785,"activeCount":98,"soonestReadout":86},[786,793],{"nctId":84,"briefTitle":85,"status":185,"phases":787,"primaryCompletion":86,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":792},[91],"2026-05","2021-08-23",45,[27,338,768],[87],{"nctId":794,"briefTitle":795,"status":110,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":803},"NCT06313203","HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)",[91],"2031-01","2034-01","2024-02-13",39,[802,768],"Intrahepatic Cholangiocarcinoma",[87],{"trials":805,"activeCount":102},[],{"trials":807,"activeCount":102},[],{"trials":809,"activeCount":102},[],{"intervention":811,"totalTrials":98,"cells":812},"Dexamethasone",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":828,"PHASE4":846,"NA":848},{"trials":814,"activeCount":102},[],{"trials":816,"activeCount":102},[],{"trials":818,"activeCount":135,"soonestReadout":46},[819],{"nctId":44,"briefTitle":45,"status":185,"phases":820,"primaryCompletion":46,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":826},[91],"2026-11-01","2018-03-16",53,[825],"Myeloma",[47,827,811],"Lenalidomide",{"trials":829,"activeCount":102},[830],{"nctId":831,"briefTitle":832,"status":166,"phases":833,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":837,"interventions":840},"NCT03011905","Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block",[92],"2019-04-05","2020-04-05","2017-01",[838,839],"Brachial Plexus Block","Pain, Postoperative",[811,841,842,843,844,845],"NaCl","Paracetamol","EtoriCoxib","Oxycodone","Ropivacaine",{"trials":847,"activeCount":102},[],{"trials":849,"activeCount":102},[],{"intervention":175,"totalTrials":733,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":853,"activeCount":102},[],{"trials":855,"activeCount":102},[],{"trials":857,"activeCount":135,"soonestReadout":745},[858,862,871],{"nctId":742,"briefTitle":743,"status":185,"phases":859,"primaryCompletion":745,"completion":113,"start":746,"enrollment":747,"conditions":860,"interventions":861},[90,91],[749],[175,732],{"nctId":863,"briefTitle":864,"status":166,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":373,"conditions":868,"interventions":870},"NCT03317327","REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors",[90,91],"2022-11-28","2017-09-09",[869],"Head and Neck Squamous Cell Carcinoma",[175],{"nctId":164,"briefTitle":165,"status":166,"phases":872,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":873,"interventions":874},[91],[33,172,173],[155,175,176,177],{"trials":876,"activeCount":102},[],{"trials":878,"activeCount":102},[],{"trials":880,"activeCount":102},[],{"intervention":882,"totalTrials":733,"cells":883},"Atezolizumab",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":885,"activeCount":102},[],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":135,"soonestReadout":894},[890,900,912],{"nctId":891,"briefTitle":892,"status":110,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":557,"conditions":897,"interventions":899},"NCT04817956","Improving Public Cancer Care by Implementing Precision Medicine in Norway",[91],"2040-03-30","2045-04-30","2021-04-01",[898],"Cancer Metastatic",[882],{"nctId":901,"briefTitle":902,"status":166,"phases":903,"primaryCompletion":904,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":911},"NCT03164993","Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer",[91],"2023-04-25","2023-09-30","2017-06-01",68,[909,910],"Cancer, Breast","Triple Negative Breast Cancer",[882,176,177],{"nctId":913,"briefTitle":914,"status":915,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":922},"NCT03644823","Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced \u002F Advanced NSCLC","TERMINATED",[91],"2020-12-31","2018-08-15",21,[921],"Non-small Cell Lung Cancer",[882],{"trials":924,"activeCount":102},[],{"trials":926,"activeCount":102},[],{"trials":928,"activeCount":102},[],{"intervention":930,"totalTrials":135,"cells":931},"Ifosfamide",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":933,"activeCount":102},[],{"trials":935,"activeCount":102},[],{"trials":937,"activeCount":135,"soonestReadout":942},[938],{"nctId":939,"briefTitle":940,"status":110,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT04776525","Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma",[91],"2026-09","2036-09","2021-04-27",49,[947],"Soft Tissue Sarcoma",[930,949],"Doxorubicin",{"trials":951,"activeCount":102},[],{"trials":953,"activeCount":102},[],{"trials":955,"activeCount":102},[],{"intervention":949,"totalTrials":135,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":135,"soonestReadout":942},[964],{"nctId":939,"briefTitle":940,"status":110,"phases":965,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":966,"interventions":967},[91],[947],[930,949],{"trials":969,"activeCount":102},[],{"trials":971,"activeCount":102},[],{"trials":973,"activeCount":102},[],{"intervention":119,"totalTrials":135,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":977,"activeCount":102},[],{"trials":979,"activeCount":102},[],{"trials":981,"activeCount":135,"soonestReadout":112},[982],{"nctId":108,"briefTitle":109,"status":110,"phases":983,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":984,"interventions":985},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":987,"activeCount":102},[],{"trials":989,"activeCount":102},[],{"trials":991,"activeCount":102},[],{"intervention":120,"totalTrials":135,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":995,"activeCount":102},[],{"trials":997,"activeCount":102},[],{"trials":999,"activeCount":135,"soonestReadout":112},[1000],{"nctId":108,"briefTitle":109,"status":110,"phases":1001,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1002,"interventions":1003},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1005,"activeCount":102},[],{"trials":1007,"activeCount":102},[],{"trials":1009,"activeCount":102},[],{"intervention":121,"totalTrials":135,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":102},[],{"trials":1015,"activeCount":102},[],{"trials":1017,"activeCount":135,"soonestReadout":112},[1018],{"nctId":108,"briefTitle":109,"status":110,"phases":1019,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1020,"interventions":1021},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1023,"activeCount":102},[],{"trials":1025,"activeCount":102},[],{"trials":1027,"activeCount":102},[],{"intervention":122,"totalTrials":135,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":102},[],{"trials":1033,"activeCount":102},[],{"trials":1035,"activeCount":135,"soonestReadout":112},[1036],{"nctId":108,"briefTitle":109,"status":110,"phases":1037,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1038,"interventions":1039},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1041,"activeCount":102},[],{"trials":1043,"activeCount":102},[],{"trials":1045,"activeCount":102},[],{"intervention":123,"totalTrials":135,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1049,"activeCount":102},[],{"trials":1051,"activeCount":102},[],{"trials":1053,"activeCount":135,"soonestReadout":112},[1054],{"nctId":108,"briefTitle":109,"status":110,"phases":1055,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1056,"interventions":1057},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1059,"activeCount":102},[],{"trials":1061,"activeCount":102},[],{"trials":1063,"activeCount":102},[],{"intervention":124,"totalTrials":135,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1067,"activeCount":102},[],{"trials":1069,"activeCount":102},[],{"trials":1071,"activeCount":135,"soonestReadout":112},[1072],{"nctId":108,"briefTitle":109,"status":110,"phases":1073,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1074,"interventions":1075},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1077,"activeCount":102},[],{"trials":1079,"activeCount":102},[],{"trials":1081,"activeCount":102},[],{"intervention":125,"totalTrials":135,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":102},[],{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":135,"soonestReadout":112},[1090],{"nctId":108,"briefTitle":109,"status":110,"phases":1091,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1092,"interventions":1093},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1095,"activeCount":102},[],{"trials":1097,"activeCount":102},[],{"trials":1099,"activeCount":102},[],{"intervention":126,"totalTrials":135,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":102},[],{"trials":1105,"activeCount":102},[],{"trials":1107,"activeCount":135,"soonestReadout":112},[1108],{"nctId":108,"briefTitle":109,"status":110,"phases":1109,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1110,"interventions":1111},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1113,"activeCount":102},[],{"trials":1115,"activeCount":102},[],{"trials":1117,"activeCount":102},[],{"intervention":127,"totalTrials":135,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":102},[],{"trials":1123,"activeCount":102},[],{"trials":1125,"activeCount":135,"soonestReadout":112},[1126],{"nctId":108,"briefTitle":109,"status":110,"phases":1127,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1128,"interventions":1129},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1131,"activeCount":102},[],{"trials":1133,"activeCount":102},[],{"trials":1135,"activeCount":102},[],{"intervention":128,"totalTrials":135,"cells":1137},{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1139,"activeCount":102},[],{"trials":1141,"activeCount":102},[],{"trials":1143,"activeCount":135,"soonestReadout":112},[1144],{"nctId":108,"briefTitle":109,"status":110,"phases":1145,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1146,"interventions":1147},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":102},[],{"trials":1153,"activeCount":102},[],{"intervention":129,"totalTrials":135,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1157,"activeCount":102},[],{"trials":1159,"activeCount":102},[],{"trials":1161,"activeCount":135,"soonestReadout":112},[1162],{"nctId":108,"briefTitle":109,"status":110,"phases":1163,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1164,"interventions":1165},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1167,"activeCount":102},[],{"trials":1169,"activeCount":102},[],{"trials":1171,"activeCount":102},[],{"intervention":131,"totalTrials":135,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1175,"activeCount":102},[],{"trials":1177,"activeCount":102},[],{"trials":1179,"activeCount":135,"soonestReadout":112},[1180],{"nctId":108,"briefTitle":109,"status":110,"phases":1181,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1182,"interventions":1183},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1185,"activeCount":102},[],{"trials":1187,"activeCount":102},[],{"trials":1189,"activeCount":102},[],{"intervention":132,"totalTrials":135,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1193,"activeCount":102},[],{"trials":1195,"activeCount":102},[],{"trials":1197,"activeCount":135,"soonestReadout":112},[1198],{"nctId":108,"briefTitle":109,"status":110,"phases":1199,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1200,"interventions":1201},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1203,"activeCount":102},[],{"trials":1205,"activeCount":102},[],{"trials":1207,"activeCount":102},[],{"intervention":133,"totalTrials":135,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1211,"activeCount":102},[],{"trials":1213,"activeCount":102},[],{"trials":1215,"activeCount":135,"soonestReadout":112},[1216],{"nctId":108,"briefTitle":109,"status":110,"phases":1217,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1218,"interventions":1219},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1221,"activeCount":102},[],{"trials":1223,"activeCount":102},[],{"trials":1225,"activeCount":102},[],{"intervention":134,"totalTrials":135,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1229,"activeCount":102},[],{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":135,"soonestReadout":112},[1234],{"nctId":108,"briefTitle":109,"status":110,"phases":1235,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1236,"interventions":1237},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"trials":1239,"activeCount":102},[],{"trials":1241,"activeCount":102},[],{"trials":1243,"activeCount":102},[],{"intervention":47,"totalTrials":135,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1247,"activeCount":102},[],{"trials":1249,"activeCount":102},[],{"trials":1251,"activeCount":135,"soonestReadout":46},[1252],{"nctId":44,"briefTitle":45,"status":185,"phases":1253,"primaryCompletion":46,"completion":821,"start":822,"enrollment":823,"conditions":1254,"interventions":1255},[91],[825],[47,827,811],{"trials":1257,"activeCount":102},[],{"trials":1259,"activeCount":102},[],{"trials":1261,"activeCount":102},[],{"intervention":827,"totalTrials":135,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1265,"activeCount":102},[],{"trials":1267,"activeCount":102},[],{"trials":1269,"activeCount":135,"soonestReadout":46},[1270],{"nctId":44,"briefTitle":45,"status":185,"phases":1271,"primaryCompletion":46,"completion":821,"start":822,"enrollment":823,"conditions":1272,"interventions":1273},[91],[825],[47,827,811],{"trials":1275,"activeCount":102},[],{"trials":1277,"activeCount":102},[],{"trials":1279,"activeCount":102},[],{"intervention":42,"totalTrials":135,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1283,"activeCount":102},[],{"trials":1285,"activeCount":102},[],{"trials":1287,"activeCount":135,"soonestReadout":41},[1288],{"nctId":39,"briefTitle":40,"status":110,"phases":1289,"primaryCompletion":41,"completion":1290,"start":1291,"enrollment":19,"conditions":1292,"interventions":1294},[90,91],"2030-12","2015-12",[1293],"Hypertension",[42],{"trials":1296,"activeCount":102},[],{"trials":1298,"activeCount":102},[],{"trials":1300,"activeCount":102},[],{"intervention":1302,"totalTrials":135,"cells":1303},"Imatinib",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1305,"activeCount":102},[],{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":135,"soonestReadout":1314},[1310],{"nctId":1311,"briefTitle":1312,"status":110,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT06119789","Precision Cancer Therapy in Rare Cancers",[91],"2033-11-30","2036-08-01","2025-03-20",96,[1319],"Rare Malignant Neoplasm",[1302,1321,1322],"Trametinib","Dabrafenib",{"trials":1324,"activeCount":102},[],{"trials":1326,"activeCount":102},[],{"trials":1328,"activeCount":102},[],{"intervention":1321,"totalTrials":135,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":102},[],{"trials":1334,"activeCount":102},[],{"trials":1336,"activeCount":135,"soonestReadout":1314},[1337],{"nctId":1311,"briefTitle":1312,"status":110,"phases":1338,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1339,"interventions":1340},[91],[1319],[1302,1321,1322],{"trials":1342,"activeCount":102},[],{"trials":1344,"activeCount":102},[],{"trials":1346,"activeCount":102},[],{"intervention":1322,"totalTrials":135,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1350,"activeCount":102},[],{"trials":1352,"activeCount":102},[],{"trials":1354,"activeCount":135,"soonestReadout":1314},[1355],{"nctId":1311,"briefTitle":1312,"status":110,"phases":1356,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1357,"interventions":1358},[91],[1319],[1302,1321,1322],{"trials":1360,"activeCount":102},[],{"trials":1362,"activeCount":102},[],{"trials":1364,"activeCount":102},[],{"intervention":1366,"totalTrials":135,"cells":1367},"TG01",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1369,"activeCount":102},[],{"trials":1371,"activeCount":102},[],{"trials":1373,"activeCount":135,"soonestReadout":1378},[1374],{"nctId":1375,"briefTitle":1376,"status":110,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":373,"conditions":1381,"interventions":1383},"NCT05841550","The TG01 Study With TG01\u002FQS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma",[90,91],"2027-05-19","2035-05-19","2023-05-19",[482,1382],"Smoldering Multiple Myeloma",[1366],{"trials":1385,"activeCount":102},[],{"trials":1387,"activeCount":102},[],{"trials":1389,"activeCount":102},[],{"intervention":1391,"totalTrials":135,"cells":1392},"Durvalumab",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1394,"activeCount":102},[],{"trials":1396,"activeCount":102},[],{"trials":1398,"activeCount":135,"soonestReadout":1403},[1399],{"nctId":1400,"briefTitle":1401,"status":185,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1412},"NCT04392505","Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study",[91],"2025-05-01","2033-05-01","2020-05-11",100,[15,1408,1409,1410,1411],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Stage III","NSCLC","NSCLC, Stage III",[1391],{"trials":1414,"activeCount":102},[],{"trials":1416,"activeCount":102},[],{"trials":1418,"activeCount":102},[],{"intervention":1420,"totalTrials":135,"cells":1421},"Fecal Microbiota Transplant",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1441,"PHASE4":1443,"NA":1445},{"trials":1423,"activeCount":102},[],{"trials":1425,"activeCount":102},[],{"trials":1427,"activeCount":135,"soonestReadout":1432},[1428],{"nctId":1429,"briefTitle":1430,"status":185,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":373,"conditions":1435,"interventions":1440},"NCT05286294","Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders",[91],"2034-03-31","2034-12-31","2022-06-28",[1436,869,1437,1438,1439,921],"Melanoma Stage IV","Cutaneous Squamous Cell Carcinoma","MSI-High","Clear Cell Renal Cell Carcinoma",[1420],{"trials":1442,"activeCount":102},[],{"trials":1444,"activeCount":102},[],{"trials":1446,"activeCount":102},[],{"intervention":1448,"totalTrials":135,"cells":1449},"Mosunetuzumab",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1451,"activeCount":102},[],{"trials":1453,"activeCount":102},[],{"trials":1455,"activeCount":135,"soonestReadout":1460},[1456],{"nctId":1457,"briefTitle":1458,"status":110,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1466},"NCT05849857","Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries",[91],"2027-06","2028-08","2023-09-11",80,[1465],"Lymphoma, Follicular",[1448],{"trials":1468,"activeCount":102},[],{"trials":1470,"activeCount":102},[],{"trials":1472,"activeCount":102},[],{"intervention":1474,"totalTrials":135,"cells":1475},"Enalapril",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1493,"PHASE4":1495,"NA":1497},{"trials":1477,"activeCount":102},[],{"trials":1479,"activeCount":102},[],{"trials":1481,"activeCount":135,"soonestReadout":1486},[1482],{"nctId":1483,"briefTitle":1484,"status":110,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":372,"enrollment":1488,"conditions":1489,"interventions":1492},"NCT06788314","A Study of Enalapril in Treatment of Venous Malformations",[91],"2029-12-01","2030-12-01",12,[1490,24,21,1491],"Venous Malformation","Vascular Malformation",[1474],{"trials":1494,"activeCount":102},[],{"trials":1496,"activeCount":102},[],{"trials":1498,"activeCount":102},[],{"intervention":52,"totalTrials":135,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1502,"activeCount":102},[],{"trials":1504,"activeCount":102},[],{"trials":1506,"activeCount":135,"soonestReadout":51},[1507],{"nctId":49,"briefTitle":50,"status":185,"phases":1508,"primaryCompletion":51,"completion":761,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1512},[91],"2015-04-01",196,[33],[52,1513],"Paclitaxel",{"trials":1515,"activeCount":102},[],{"trials":1517,"activeCount":102},[],{"trials":1519,"activeCount":102},[],{"intervention":1513,"totalTrials":135,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1523,"activeCount":102},[],{"trials":1525,"activeCount":102},[],{"trials":1527,"activeCount":135,"soonestReadout":51},[1528],{"nctId":49,"briefTitle":50,"status":185,"phases":1529,"primaryCompletion":51,"completion":761,"start":1509,"enrollment":1510,"conditions":1530,"interventions":1531},[91],[33],[52,1513],{"trials":1533,"activeCount":102},[],{"trials":1535,"activeCount":102},[],{"trials":1537,"activeCount":102},[],{"intervention":1539,"totalTrials":135,"cells":1540},"Oxytocin nasal spray",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1542,"activeCount":102},[],{"trials":1544,"activeCount":102},[],{"trials":1546,"activeCount":135,"soonestReadout":1551},[1547],{"nctId":1548,"briefTitle":1549,"status":368,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT05934812","Intranasal Oxytocin in Youth With Autism",[91],"2025-11-04","2024-09-18",128,[1555],"Autism Spectrum Disorder",[1539],{"trials":1558,"activeCount":102},[],{"trials":1560,"activeCount":102},[],{"trials":1562,"activeCount":102},[],{"intervention":1564,"totalTrials":135,"cells":1565},"LTX-315 + pembrolizumab",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1567,"activeCount":102},[],{"trials":1569,"activeCount":102},[],{"trials":1571,"activeCount":135,"soonestReadout":788},[1572],{"nctId":1573,"briefTitle":1574,"status":110,"phases":1575,"primaryCompletion":788,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT06651151","NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III\u002FIV Melanoma",[91],"2031-05","2024-11-01",27,[1580],"Melanoma Stage IIIB-IV",[1564],{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":102},[],{"trials":1587,"activeCount":102},[],{"intervention":130,"totalTrials":1589,"cells":1590},5,{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1592,"activeCount":102},[],{"trials":1594,"activeCount":102},[],{"trials":1596,"activeCount":135,"soonestReadout":112},[1597,1601,1613,1622],{"nctId":108,"briefTitle":109,"status":110,"phases":1598,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":1599,"interventions":1600},[91],[117],[119,120,121,122,123,124,125,126,127,97,128,129,130,131,132,133,134],{"nctId":1602,"briefTitle":1603,"status":166,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":28,"conditions":1607,"interventions":1609},"NCT02677155","Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma",[91],"2021-02","2016-01",[1608],"Follicular Lymphoma",[1610,1611,1612,130],"Rituximab","Autologous dendritic cells","GM-CSF",{"nctId":1614,"briefTitle":1615,"status":915,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":34,"conditions":1619,"interventions":1621},"NCT02691026","A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery",[91],"2020-12","2016-06",[1620],"Malignant Peripheral Nerve Sheath Tumour (MPNST)",[130],{"nctId":1623,"briefTitle":1624,"status":915,"phases":1625,"primaryCompletion":1626,"completion":1627,"start":1628,"enrollment":1488,"conditions":1629,"interventions":1631},"NCT03013127","A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery",[91],"2018-11-26","2019-01-31","2017-05-30",[1630],"Osteosarcoma",[130],{"trials":1633,"activeCount":102},[],{"trials":1635,"activeCount":102},[],{"trials":1637,"activeCount":102},[1638],{"nctId":1639,"briefTitle":1640,"status":915,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1463,"conditions":1644,"interventions":1645},"NCT04557007","Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients",[],"2022-10-01","2020-09-01",[1410],[130],{"intervention":1647,"totalTrials":135,"cells":1648},"Molgramostim",{"EARLY_PHASE1":1649,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1650,"activeCount":135,"soonestReadout":1655},[1651],{"nctId":1652,"briefTitle":1653,"status":110,"phases":1654,"primaryCompletion":1655,"completion":1433,"start":1656,"enrollment":28,"conditions":1657,"interventions":1659},"NCT07341360","Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei",[89],"2029-12-31","2025-10-13",[1658],"Pseudomyxoma Peritonei",[1647,1660],"Tislelizumab",{"trials":1662,"activeCount":102},[],{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":102},[],{"intervention":1660,"totalTrials":135,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":135,"soonestReadout":1655},[1675],{"nctId":1652,"briefTitle":1653,"status":110,"phases":1676,"primaryCompletion":1655,"completion":1433,"start":1656,"enrollment":28,"conditions":1677,"interventions":1678},[89],[1658],[1647,1660],{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[],{"trials":1684,"activeCount":102},[],{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":102},[],{"intervention":1690,"totalTrials":135,"cells":1691},"Botox",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1693,"activeCount":102},[],{"trials":1695,"activeCount":102},[],{"trials":1697,"activeCount":102},[],{"trials":1699,"activeCount":102},[],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":135,"soonestReadout":1708},[1704],{"nctId":1705,"briefTitle":1706,"status":110,"phases":1707,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":115,"conditions":1710,"interventions":1713},"NCT05218785","Treatment of Gastrocnemius Tightness and Subsequent Chronic Plantar Fasciitis with Botulinum Toxin a",[],"2026-01","2022-01-13",[1711,1712],"Plantar Fascitis","Gastrocnemius Tightness",[1690],{"intervention":62,"totalTrials":135,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1717,"activeCount":102},[],{"trials":1719,"activeCount":102},[],{"trials":1721,"activeCount":102},[],{"trials":1723,"activeCount":102},[],{"trials":1725,"activeCount":102},[],{"trials":1727,"activeCount":135,"soonestReadout":61},[1728],{"nctId":59,"briefTitle":60,"status":185,"phases":1729,"primaryCompletion":61,"completion":745,"start":1730,"enrollment":1731,"conditions":1732,"interventions":1735},[],"2018-01-01",251,[1733,768,1734,767],"Locally Advanced Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma",[62],{"intervention":1737,"totalTrials":135,"cells":1738},"Tenofovir disoproxil",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1740,"activeCount":102},[],{"trials":1742,"activeCount":102},[],{"trials":1744,"activeCount":102},[],{"trials":1746,"activeCount":102},[],{"trials":1748,"activeCount":102},[],{"trials":1750,"activeCount":135,"soonestReadout":188},[1751],{"nctId":1752,"briefTitle":1753,"status":185,"phases":1754,"primaryCompletion":188,"completion":188,"start":1755,"enrollment":1756,"conditions":1757,"interventions":1759},"NCT02344498","Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa",[],"2015-01",7350,[1758],"Hepatitis B",[1737],{"intervention":1761,"totalTrials":135,"cells":1762},"Meropenem 1000 mg",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1764,"activeCount":102},[],{"trials":1766,"activeCount":102},[],{"trials":1768,"activeCount":102},[],{"trials":1770,"activeCount":102},[],{"trials":1772,"activeCount":102},[],{"trials":1774,"activeCount":135,"soonestReadout":188},[1775],{"nctId":1776,"briefTitle":1777,"status":110,"phases":1778,"primaryCompletion":188,"completion":1460,"start":1779,"enrollment":404,"conditions":1780,"interventions":1782},"NCT05578586","A Pilot Study for Optimizing Meropenem Administration in the ICU",[94],"2021-12-14",[1781],"Drug Effect",[1761],{"intervention":1784,"totalTrials":135,"cells":1785},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1787,"activeCount":102},[],{"trials":1789,"activeCount":102},[],{"trials":1791,"activeCount":102},[],{"trials":1793,"activeCount":102},[],{"trials":1795,"activeCount":102},[],{"trials":1797,"activeCount":135,"soonestReadout":1802},[1798],{"nctId":1799,"briefTitle":1800,"status":110,"phases":1801,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":1804,"conditions":1805,"interventions":1806},"NCT06586983","Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia",[],"2028-09-05","2024-09-04",4500,[1758],[1784],{"intervention":1808,"totalTrials":135,"cells":1809},"Nerve conduction Studies",{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1814,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1811,"activeCount":102},[],{"trials":1813,"activeCount":102},[],{"trials":1815,"activeCount":102},[],{"trials":1817,"activeCount":102},[],{"trials":1819,"activeCount":102},[],{"trials":1821,"activeCount":135,"soonestReadout":1826},[1822],{"nctId":1823,"briefTitle":1824,"status":110,"phases":1825,"primaryCompletion":1826,"completion":555,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1833},"NCT03862365","Exploring the Genetics of Neuropathic Pain",[],"2027-01-01","2018-08-01",5000,[1830,1831,1832],"Neuropathic Pain","Genetic Predisposition","Polyneuropathies",[1808],{"intervention":1835,"totalTrials":733,"cells":1836},"Fentanyl",{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1843,"PHASE4":1858,"NA":1882},{"trials":1838,"activeCount":102},[],{"trials":1840,"activeCount":102},[],{"trials":1842,"activeCount":102},[],{"trials":1844,"activeCount":102},[1845],{"nctId":1846,"briefTitle":1847,"status":166,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1855},"NCT05137184","A Comparison of Three Regimens of Acute Pain Management: Methoxyflurane; Intranasal Fentanyl; Intravenous Morphine",[92],"2023-04-22","2021-11-12",338,[1853,1854],"Acute Pain","Ambulances",[1856,1835,1857],"Methoxyflurane","Morphine hydrochloride",{"trials":1859,"activeCount":102},[1860,1870],{"nctId":1861,"briefTitle":1862,"status":166,"phases":1863,"primaryCompletion":1864,"completion":1864,"start":1865,"enrollment":1488,"conditions":1866,"interventions":1869},"NCT03894800","Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl",[93],"2019-10-29","2019-04-23",[1853,1867,1868],"Trauma","Hypovolemia",[1856,1835,1835,841],{"nctId":1871,"briefTitle":1872,"status":220,"phases":1873,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":147,"conditions":1877,"interventions":1881},"NCT02587273","The Pharmacokinetics of Fentanyl in Intensive Care Patients",[93],"2017-09","2017-11","2015-10",[1878,1879,1880],"Multiple Organ Failure","Critical Care","Intensive Care",[1835],{"trials":1883,"activeCount":102},[],{"intervention":1885,"totalTrials":733,"cells":1886},"Placebos",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1914,"PHASE4":1916,"NA":1930},{"trials":1888,"activeCount":102},[],{"trials":1890,"activeCount":102},[],{"trials":1892,"activeCount":102},[1893,1904],{"nctId":1894,"briefTitle":1895,"status":166,"phases":1896,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1317,"conditions":1899,"interventions":1902},"NCT04838145","The Diabetes Virus Detection and Intervention Trial",[91],"2020-10-25","2018-08-30",[1900,1901],"Type1 Diabetes Mellitus","Enterovirus",[1903,1885],"Ribavirin + Pleconaril",{"nctId":1905,"briefTitle":1906,"status":166,"phases":1907,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":115,"conditions":1910,"interventions":1912},"NCT04304755","Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)",[91],"2024-01-24","2021-10-25",[1911],"Neovascular Age-related Macular Degeneration",[1913,1885],"Zoledronic Acid 5 MG in 5 ML",{"trials":1915,"activeCount":102},[],{"trials":1917,"activeCount":102},[1918],{"nctId":1919,"briefTitle":1920,"status":220,"phases":1921,"primaryCompletion":1922,"completion":1617,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1928},"NCT03446534","The Norwegian Antibiotics for Pneumonia in Children Study",[93],"2020-05","2018-03-07",884,[1926,1927],"Pneumonia Childhood","Lower Respiratory Tract Infection",[1929,1885],"Amoxicillin",{"trials":1931,"activeCount":102},[],{"intervention":1856,"totalTrials":98,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1946,"NA":1952},{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":102},[],{"trials":1939,"activeCount":102},[],{"trials":1941,"activeCount":102},[1942],{"nctId":1846,"briefTitle":1847,"status":166,"phases":1943,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1944,"interventions":1945},[92],[1853,1854],[1856,1835,1857],{"trials":1947,"activeCount":102},[1948],{"nctId":1861,"briefTitle":1862,"status":166,"phases":1949,"primaryCompletion":1864,"completion":1864,"start":1865,"enrollment":1488,"conditions":1950,"interventions":1951},[93],[1853,1867,1868],[1856,1835,1835,841],{"trials":1953,"activeCount":102},[],{"intervention":841,"totalTrials":98,"cells":1955},{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1968,"NA":1974},{"trials":1957,"activeCount":102},[],{"trials":1959,"activeCount":102},[],{"trials":1961,"activeCount":102},[],{"trials":1963,"activeCount":102},[1964],{"nctId":831,"briefTitle":832,"status":166,"phases":1965,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":1966,"interventions":1967},[92],[838,839],[811,841,842,843,844,845],{"trials":1969,"activeCount":102},[1970],{"nctId":1861,"briefTitle":1862,"status":166,"phases":1971,"primaryCompletion":1864,"completion":1864,"start":1865,"enrollment":1488,"conditions":1972,"interventions":1973},[93],[1853,1867,1868],[1856,1835,1835,841],{"trials":1975,"activeCount":102},[],{"intervention":1929,"totalTrials":98,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1998,"NA":2004},{"trials":1979,"activeCount":102},[],{"trials":1981,"activeCount":102},[],{"trials":1983,"activeCount":102},[],{"trials":1985,"activeCount":102},[1986],{"nctId":1987,"briefTitle":1988,"status":166,"phases":1989,"primaryCompletion":1990,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1997},"NCT02323412","Antibiotics In Modic Changes",[92],"2018-09-21","2018-11-06","2015-06",180,[1995,1996],"Low Back Pain","Modic Changes Type I or II Seen on MRI",[1929],{"trials":1999,"activeCount":102},[2000],{"nctId":1919,"briefTitle":1920,"status":220,"phases":2001,"primaryCompletion":1922,"completion":1617,"start":1923,"enrollment":1924,"conditions":2002,"interventions":2003},[93],[1926,1927],[1929,1885],{"trials":2005,"activeCount":102},[],{"intervention":2007,"totalTrials":98,"cells":2008},"Rosuvastatin",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2026,"NA":2037},{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[2017],{"nctId":2018,"briefTitle":2019,"status":166,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":419,"conditions":2023,"interventions":2025},"NCT00505154","Effect of Rosuvastatin on Left Ventricular Remodeling",[92],"2013-07","2007-07",[2024],"Dilated Cardiomyopathy",[2007],{"trials":2027,"activeCount":102},[2028],{"nctId":2029,"briefTitle":2030,"status":166,"phases":2031,"primaryCompletion":1618,"completion":1618,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2036},"NCT01582165","Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance",[93],"2012-06",66,[2035],"Angina Pectoris",[2007],{"trials":2038,"activeCount":102},[],{"intervention":2040,"totalTrials":98,"cells":2041},"Rifaximin",{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2059,"PHASE4":2061,"NA":2072},{"trials":2043,"activeCount":102},[],{"trials":2045,"activeCount":102},[],{"trials":2047,"activeCount":102},[2048],{"nctId":2049,"briefTitle":2050,"status":220,"phases":2051,"primaryCompletion":2052,"completion":2053,"start":2054,"enrollment":147,"conditions":2055,"interventions":2057},"NCT02637167","GutHeart: Targeting Gut Microbiota to Treat Heart Failure",[91],"2019-06-20","2019-12-31","2016-03-11",[2056],"Systolic Heart Failure",[2040,2058],"Saccharomyces boulardii",{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[2063],{"nctId":2064,"briefTitle":2065,"status":166,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":115,"conditions":2069,"interventions":2071},"NCT01946906","The Rifaximin Study in CVID",[93],"2014-12","2013-10",[2070],"Common Variable Immunodeficiency (CVID)",[2040],{"trials":2073,"activeCount":102},[],{"intervention":2075,"totalTrials":98,"cells":2076},"Pregabalin",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2108},{"trials":2078,"activeCount":102},[],{"trials":2080,"activeCount":102},[],{"trials":2082,"activeCount":102},[],{"trials":2084,"activeCount":102},[],{"trials":2086,"activeCount":102},[2087,2097],{"nctId":2088,"briefTitle":2089,"status":166,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1488,"conditions":2093,"interventions":2094},"NCT01419405","Pregabalin and Remifentanil - Analgesia and Ventilation",[93],"2012-03","2011-12",[24],[2075,2095,2096],"Remifentanil","sugar pill, saline",{"nctId":2098,"briefTitle":2099,"status":166,"phases":2100,"primaryCompletion":2101,"completion":2102,"start":2103,"enrollment":1463,"conditions":2104,"interventions":2106},"NCT01059331","Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy",[93],"2011-10","2012-12","2010-02",[2105],"Living Donors",[2075,2107],"Sugar pill",{"trials":2109,"activeCount":102},[],{"intervention":2095,"totalTrials":98,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2135},{"trials":2113,"activeCount":102},[],{"trials":2115,"activeCount":102},[],{"trials":2117,"activeCount":102},[],{"trials":2119,"activeCount":102},[],{"trials":2121,"activeCount":102},[2122,2126],{"nctId":2088,"briefTitle":2089,"status":166,"phases":2123,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1488,"conditions":2124,"interventions":2125},[93],[24],[2075,2095,2096],{"nctId":2127,"briefTitle":2128,"status":166,"phases":2129,"primaryCompletion":2102,"completion":2102,"start":2130,"enrollment":2131,"conditions":2132,"interventions":2134},"NCT01702389","Opioid-induced Hyperalgesia After Remifentanil Infusion",[93],"2012-10",16,[2133],"Hyperalgesia",[2095],{"trials":2136,"activeCount":102},[],{"intervention":844,"totalTrials":98,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2151,"NA":2168},{"trials":2140,"activeCount":102},[],{"trials":2142,"activeCount":102},[],{"trials":2144,"activeCount":102},[],{"trials":2146,"activeCount":102},[2147],{"nctId":831,"briefTitle":832,"status":166,"phases":2148,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":2149,"interventions":2150},[92],[838,839],[811,841,842,843,844,845],{"trials":2152,"activeCount":102},[2153],{"nctId":2154,"briefTitle":2155,"status":166,"phases":2156,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":2159,"conditions":2160,"interventions":2166},"NCT03314792","Effects of Tapentadol Versus Oxycodone After Hysterectomy.",[93],"2019-02-28","2017-12-04",86,[839,2161,2162,2163,2164,2165],"Pain Uterus","Pain, Acute","Opioid Use","Analgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use","Visceral Pain",[2167,844],"Tapentadol",{"trials":2169,"activeCount":102},[],{"intervention":2171,"totalTrials":98,"cells":2172},"Carbetocin",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2181,"NA":2204},{"trials":2174,"activeCount":102},[],{"trials":2176,"activeCount":102},[],{"trials":2178,"activeCount":102},[],{"trials":2180,"activeCount":102},[],{"trials":2182,"activeCount":102},[2183,2193],{"nctId":2184,"briefTitle":2185,"status":166,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":115,"conditions":2189,"interventions":2191},"NCT02528136","The Clinical Carbetocin Myocardium Trial",[93],"2019-01-28","2015-09",[2190],"Pregnancy",[2171,2192],"Oxytocin",{"nctId":2194,"briefTitle":2195,"status":166,"phases":2196,"primaryCompletion":2197,"completion":2198,"start":2199,"enrollment":2200,"conditions":2201,"interventions":2203},"NCT03899961","Carbetocin Myocardium Trial 2014 Part 2",[93],"2022-03-01","2022-04-15","2019-04-02",240,[2202],"Pregnancy Complications",[2192,2171],{"trials":2205,"activeCount":102},[],{"intervention":2192,"totalTrials":98,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2226},{"trials":2209,"activeCount":102},[],{"trials":2211,"activeCount":102},[],{"trials":2213,"activeCount":102},[],{"trials":2215,"activeCount":102},[],{"trials":2217,"activeCount":102},[2218,2222],{"nctId":2184,"briefTitle":2185,"status":166,"phases":2219,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":115,"conditions":2220,"interventions":2221},[93],[2190],[2171,2192],{"nctId":2194,"briefTitle":2195,"status":166,"phases":2223,"primaryCompletion":2197,"completion":2198,"start":2199,"enrollment":2200,"conditions":2224,"interventions":2225},[93],[2202],[2192,2171],{"trials":2227,"activeCount":102},[],{"intervention":2229,"totalTrials":135,"cells":2230},"adrenalin",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2248},{"trials":2232,"activeCount":102},[],{"trials":2234,"activeCount":102},[],{"trials":2236,"activeCount":102},[],{"trials":2238,"activeCount":102},[],{"trials":2240,"activeCount":102},[2241],{"nctId":2242,"briefTitle":2243,"status":166,"phases":2244,"primaryCompletion":1606,"completion":1606,"start":2245,"enrollment":115,"conditions":2246,"interventions":2247},"NCT00685672","Safety of Epidural Fentanyl and Adrenalin During Childbirth",[93],"2008-08",[2190,24],[2229],{"trials":2249,"activeCount":102},[],{"intervention":2251,"totalTrials":135,"cells":2252},"Alfentanil 0.5mg\u002Fml",{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2259,"PHASE4":2261,"NA":2273},{"trials":2254,"activeCount":102},[],{"trials":2256,"activeCount":102},[],{"trials":2258,"activeCount":102},[],{"trials":2260,"activeCount":102},[],{"trials":2262,"activeCount":102},[2263],{"nctId":2264,"briefTitle":2265,"status":166,"phases":2266,"primaryCompletion":2267,"completion":2101,"start":2268,"enrollment":2269,"conditions":2270,"interventions":2272},"NCT01518608","Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach",[93],"2011-09","2009-09",84,[2271],"Anesthesia Intubation Complication",[2251],{"trials":2274,"activeCount":102},[],{"intervention":2276,"totalTrials":135,"cells":2277},"Q10",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2298},{"trials":2279,"activeCount":102},[],{"trials":2281,"activeCount":102},[],{"trials":2283,"activeCount":102},[],{"trials":2285,"activeCount":102},[],{"trials":2287,"activeCount":102},[2288],{"nctId":2289,"briefTitle":2290,"status":166,"phases":2291,"primaryCompletion":2292,"completion":2292,"start":2293,"enrollment":115,"conditions":2294,"interventions":2296},"NCT00113477","The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy",[93],"2007-12","2005-05",[2295],"Statin Therapy",[2276,2297],"Selen",{"trials":2299,"activeCount":102},[],{"intervention":2297,"totalTrials":135,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2316},{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":102},[],{"trials":2307,"activeCount":102},[],{"trials":2309,"activeCount":102},[],{"trials":2311,"activeCount":102},[2312],{"nctId":2289,"briefTitle":2290,"status":166,"phases":2313,"primaryCompletion":2292,"completion":2292,"start":2293,"enrollment":115,"conditions":2314,"interventions":2315},[93],[2295],[2276,2297],{"trials":2317,"activeCount":102},[],{"intervention":2319,"totalTrials":135,"cells":2320},"xiapex",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2341},{"trials":2322,"activeCount":102},[],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"trials":2330,"activeCount":102},[2331],{"nctId":2332,"briefTitle":2333,"status":220,"phases":2334,"primaryCompletion":2335,"completion":2336,"start":2337,"enrollment":404,"conditions":2338,"interventions":2340},"NCT02476461","Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture",[93],"2016-04","2021-01","2015-04",[2339],"Dupuytrens Contracture",[2319],{"trials":2342,"activeCount":102},[],{"intervention":2344,"totalTrials":135,"cells":2345},"Zoledronic Acid Injectable Product",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2366},{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":102},[2356],{"nctId":2357,"briefTitle":2358,"status":915,"phases":2359,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":1589,"conditions":2362,"interventions":2365},"NCT03576599","Intravenous Bisphosphonate in Stress Fracture Treatment -A Randomised Controlled Double Blinded Multicenter Trial",[93],"2019-06-26","2017-06-29",[2363,2364],"Stress Fracture Foot","Stress Fracture Ankle",[2344],{"trials":2367,"activeCount":102},[],{"intervention":2369,"totalTrials":135,"cells":2370},"Aripiprazole",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2392},{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":102},[],{"trials":2376,"activeCount":102},[],{"trials":2378,"activeCount":102},[],{"trials":2380,"activeCount":102},[2381],{"nctId":2382,"briefTitle":2383,"status":166,"phases":2384,"primaryCompletion":2385,"completion":2385,"start":418,"enrollment":2386,"conditions":2387,"interventions":2390},"NCT01161277","Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning",[93],"2011-06",54,[2388,2389],"Psychosis","Schizophrenia",[2369,2391],"Haloperidol",{"trials":2393,"activeCount":102},[],{"intervention":2391,"totalTrials":135,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2404,"NA":2410},{"trials":2397,"activeCount":102},[],{"trials":2399,"activeCount":102},[],{"trials":2401,"activeCount":102},[],{"trials":2403,"activeCount":102},[],{"trials":2405,"activeCount":102},[2406],{"nctId":2382,"briefTitle":2383,"status":166,"phases":2407,"primaryCompletion":2385,"completion":2385,"start":418,"enrollment":2386,"conditions":2408,"interventions":2409},[93],[2388,2389],[2369,2391],{"trials":2411,"activeCount":102},[],{"intervention":2413,"totalTrials":135,"cells":2414},"Saxagliptin",{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2433},{"trials":2416,"activeCount":102},[],{"trials":2418,"activeCount":102},[],{"trials":2420,"activeCount":102},[],{"trials":2422,"activeCount":102},[],{"trials":2424,"activeCount":102},[2425],{"nctId":2426,"briefTitle":2427,"status":166,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":2091,"enrollment":1488,"conditions":2430,"interventions":2432},"NCT01552018","Saxagliptin and Atherosclerosis",[93],"2014-02",[30,2431],"Diabetes Mellitus Type 2",[2413],{"trials":2434,"activeCount":102},[],{"intervention":2436,"totalTrials":135,"cells":2437},"Ringer acetate",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2458},{"trials":2439,"activeCount":102},[],{"trials":2441,"activeCount":102},[],{"trials":2443,"activeCount":102},[],{"trials":2445,"activeCount":102},[],{"trials":2447,"activeCount":102},[2448],{"nctId":2449,"briefTitle":2450,"status":166,"phases":2451,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":19,"conditions":2454,"interventions":2457},"NCT05705115","Acetated Ringer´s Solution in Experimental Hypovolemia",[93],"2025-10-30","2024-03-02",[1868,2455,2456],"Fluid Loss","Hemodynamic Instability",[2436],{"trials":2459,"activeCount":102},[],{"intervention":2461,"totalTrials":135,"cells":2462},"levetiracetam",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2483},{"trials":2464,"activeCount":102},[],{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[2473],{"nctId":2474,"briefTitle":2475,"status":220,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":747,"conditions":2479,"interventions":2482},"NCT00393614","Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA)",[93],"2010-03","2007-05",[2480,2481],"Subclinical Sleep-Activated Epileptiform Activity","CSWS",[2461],{"trials":2484,"activeCount":102},[],{"intervention":2486,"totalTrials":135,"cells":2487},"Triamcinolone Hexacetonide 20 MG\u002FML",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2494,"PHASE4":2496,"NA":2508},{"trials":2489,"activeCount":102},[],{"trials":2491,"activeCount":102},[],{"trials":2493,"activeCount":102},[],{"trials":2495,"activeCount":102},[],{"trials":2497,"activeCount":102},[2498],{"nctId":2499,"briefTitle":2500,"status":166,"phases":2501,"primaryCompletion":2502,"completion":2503,"start":2504,"enrollment":2505,"conditions":2506,"interventions":2507},"NCT04614311","Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).",[93],"2024-11-07","2025-02-06","2020-12-01",189,[149],[2486],{"trials":2509,"activeCount":102},[],{"intervention":2511,"totalTrials":135,"cells":2512},"Rifampin-combination therapy",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2533},{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":102},[],{"trials":2518,"activeCount":102},[],{"trials":2520,"activeCount":102},[],{"trials":2522,"activeCount":102},[2523],{"nctId":2524,"briefTitle":2525,"status":220,"phases":2526,"primaryCompletion":2102,"completion":2067,"start":2527,"enrollment":1406,"conditions":2528,"interventions":2531},"NCT00423982","Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty",[93],"2006-04",[2529,2530],"Prosthesis-related Infections","Staphylococcal Infections",[2511,2532],"Monotherapy",{"trials":2534,"activeCount":102},[],{"intervention":2532,"totalTrials":135,"cells":2536},{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2551},{"trials":2538,"activeCount":102},[],{"trials":2540,"activeCount":102},[],{"trials":2542,"activeCount":102},[],{"trials":2544,"activeCount":102},[],{"trials":2546,"activeCount":102},[2547],{"nctId":2524,"briefTitle":2525,"status":220,"phases":2548,"primaryCompletion":2102,"completion":2067,"start":2527,"enrollment":1406,"conditions":2549,"interventions":2550},[93],[2529,2530],[2511,2532],{"trials":2552,"activeCount":102},[],{"intervention":2554,"totalTrials":135,"cells":2555},"Sacubitril \u002F Valsartan Oral",{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2575},{"trials":2557,"activeCount":102},[],{"trials":2559,"activeCount":102},[],{"trials":2561,"activeCount":102},[],{"trials":2563,"activeCount":102},[],{"trials":2565,"activeCount":102},[2566],{"nctId":2567,"briefTitle":2568,"status":220,"phases":2569,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":115,"conditions":2572,"interventions":2574},"NCT03553303","Pharmacodynamic Effects of Sacubitril\u002FValsartan on Natriuretic Peptides, Angiotensin and Neprilysin",[93],"2022-05","2018-10-16",[2573],"Heart Failure, Systolic",[2554],{"trials":2576,"activeCount":102},[],{"intervention":2096,"totalTrials":135,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2593},{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"trials":2586,"activeCount":102},[],{"trials":2588,"activeCount":102},[2589],{"nctId":2088,"briefTitle":2089,"status":166,"phases":2590,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1488,"conditions":2591,"interventions":2592},[93],[24],[2075,2095,2096],{"trials":2594,"activeCount":102},[],{"intervention":2107,"totalTrials":135,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2611},{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":102},[],{"trials":2602,"activeCount":102},[],{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[2607],{"nctId":2098,"briefTitle":2099,"status":166,"phases":2608,"primaryCompletion":2101,"completion":2102,"start":2103,"enrollment":1463,"conditions":2609,"interventions":2610},[93],[2105],[2075,2107],{"trials":2612,"activeCount":102},[],{"intervention":2614,"totalTrials":135,"cells":2615},"carbetocin 100 µg",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2624,"NA":2637},{"trials":2617,"activeCount":102},[],{"trials":2619,"activeCount":102},[],{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":102},[2626],{"nctId":2627,"briefTitle":2628,"status":166,"phases":2629,"primaryCompletion":2630,"completion":2101,"start":2631,"enrollment":2632,"conditions":2633,"interventions":2635},"NCT00977769","Carbetocin Versus Oxytocin and Hemodynamic Effects",[93],"2011-08","2009-11",76,[2634],"Effects of; Anesthesia, in Pregnancy",[2614,2636],"oxytocin 5 u",{"trials":2638,"activeCount":102},[],{"intervention":2636,"totalTrials":135,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2645,"PHASE3":2647,"PHASE4":2649,"NA":2655},{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":102},[],{"trials":2646,"activeCount":102},[],{"trials":2648,"activeCount":102},[],{"trials":2650,"activeCount":102},[2651],{"nctId":2627,"briefTitle":2628,"status":166,"phases":2652,"primaryCompletion":2630,"completion":2101,"start":2631,"enrollment":2632,"conditions":2653,"interventions":2654},[93],[2634],[2614,2636],{"trials":2656,"activeCount":102},[],{"intervention":2658,"totalTrials":135,"cells":2659},"Dexmedetomidine",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2666,"PHASE4":2668,"NA":2685},{"trials":2661,"activeCount":102},[],{"trials":2663,"activeCount":102},[],{"trials":2665,"activeCount":102},[],{"trials":2667,"activeCount":102},[],{"trials":2669,"activeCount":102},[2670],{"nctId":2671,"briefTitle":2672,"status":220,"phases":2673,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":2678,"interventions":2682},"NCT05029050","Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart Surgery",[93],"2024-07","2025-01","2022-01-17",900,[2679,2680,2681],"Delirium","Cognitive Decline","Frailty",[2658,2683,2684],"Clonidine","Natriumchlorid",{"trials":2686,"activeCount":102},[],{"intervention":2684,"totalTrials":135,"cells":2688},{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2693,"PHASE3":2695,"PHASE4":2697,"NA":2703},{"trials":2690,"activeCount":102},[],{"trials":2692,"activeCount":102},[],{"trials":2694,"activeCount":102},[],{"trials":2696,"activeCount":102},[],{"trials":2698,"activeCount":102},[2699],{"nctId":2671,"briefTitle":2672,"status":220,"phases":2700,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":2701,"interventions":2702},[93],[2679,2680,2681],[2658,2683,2684],{"trials":2704,"activeCount":102},[],{"intervention":2706,"totalTrials":135,"cells":2707},"\"Nycoplus Magnesium\"",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2716,"NA":2727},{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[2718],{"nctId":2719,"briefTitle":2720,"status":166,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":790,"conditions":2724,"interventions":2726},"NCT00525317","Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ?",[93],"2004-09","2002-01",[2725],"Cramps",[2706],{"trials":2728,"activeCount":102},[],{"intervention":2730,"totalTrials":135,"cells":2731},"aPCC, aPCC + TXA",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2740,"NA":2751},{"trials":2733,"activeCount":102},[],{"trials":2735,"activeCount":102},[],{"trials":2737,"activeCount":102},[],{"trials":2739,"activeCount":102},[],{"trials":2741,"activeCount":102},[2742],{"nctId":2743,"briefTitle":2744,"status":166,"phases":2745,"primaryCompletion":2130,"completion":2130,"start":2101,"enrollment":2746,"conditions":2747,"interventions":2749},"NCT01800435","A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor",[93],6,[2748],"Hereditary Factor VIII Deficiency Disease With Inhibitor",[2730,2750],"rFVIIa, rFVIIa + TXA",{"trials":2752,"activeCount":102},[],{"intervention":2750,"totalTrials":135,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2761,"PHASE4":2763,"NA":2769},{"trials":2756,"activeCount":102},[],{"trials":2758,"activeCount":102},[],{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":102},[],{"trials":2764,"activeCount":102},[2765],{"nctId":2743,"briefTitle":2744,"status":166,"phases":2766,"primaryCompletion":2130,"completion":2130,"start":2101,"enrollment":2746,"conditions":2767,"interventions":2768},[93],[2748],[2730,2750],{"trials":2770,"activeCount":102},[],{"intervention":2772,"totalTrials":135,"cells":2773},"Ropivacaine concentration low",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2795},{"trials":2775,"activeCount":102},[],{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":102},[],{"trials":2783,"activeCount":102},[2784],{"nctId":2785,"briefTitle":2786,"status":166,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":1463,"conditions":2790,"interventions":2793},"NCT06950372","Ropivacaine Concentration and Rebound Pain",[93],"2026-04-08","2025-02-14",[2791,2792],"Radius Fracture Distal","Rebound Pain",[2772,2794],"Ropivacaine concentration high",{"trials":2796,"activeCount":102},[],{"intervention":2794,"totalTrials":135,"cells":2798},{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2813},{"trials":2800,"activeCount":102},[],{"trials":2802,"activeCount":102},[],{"trials":2804,"activeCount":102},[],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[2809],{"nctId":2785,"briefTitle":2786,"status":166,"phases":2810,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":1463,"conditions":2811,"interventions":2812},[93],[2791,2792],[2772,2794],{"trials":2814,"activeCount":102},[],{"intervention":2816,"totalTrials":135,"cells":2817},"levosimendan",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2826,"NA":2839},{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[],{"trials":2823,"activeCount":102},[],{"trials":2825,"activeCount":102},[],{"trials":2827,"activeCount":102},[2828],{"nctId":2829,"briefTitle":2830,"status":166,"phases":2831,"primaryCompletion":2267,"completion":2091,"start":2832,"enrollment":2833,"conditions":2834,"interventions":2838},"NCT00324766","Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.",[93],"2006-06",61,[2835,2836,2837],"Myocardial Infarction","Heart Failure","Cardiogenic Shock",[2816],{"trials":2840,"activeCount":102},[],{"intervention":2842,"totalTrials":135,"cells":2843},"atorvastatin",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2863},{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[],{"trials":2849,"activeCount":102},[],{"trials":2851,"activeCount":102},[],{"trials":2853,"activeCount":102},[2854],{"nctId":2855,"briefTitle":2856,"status":166,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":823,"conditions":2860,"interventions":2862},"NCT00199745","Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity",[93],"2008-12","2005-10",[2861],"Muscular Diseases",[2842],{"trials":2864,"activeCount":102},[],{"intervention":2167,"totalTrials":135,"cells":2866},{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2873,"PHASE4":2875,"NA":2881},{"trials":2868,"activeCount":102},[],{"trials":2870,"activeCount":102},[],{"trials":2872,"activeCount":102},[],{"trials":2874,"activeCount":102},[],{"trials":2876,"activeCount":102},[2877],{"nctId":2154,"briefTitle":2155,"status":166,"phases":2878,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":2159,"conditions":2879,"interventions":2880},[93],[839,2161,2162,2163,2164,2165],[2167,844],{"trials":2882,"activeCount":102},[],{"intervention":2884,"totalTrials":135,"cells":2885},"Patiromer Oral Product",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2906},{"trials":2887,"activeCount":102},[],{"trials":2889,"activeCount":102},[],{"trials":2891,"activeCount":102},[],{"trials":2893,"activeCount":102},[],{"trials":2895,"activeCount":102},[2896],{"nctId":2897,"briefTitle":2898,"status":166,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":25,"conditions":2902,"interventions":2905},"NCT05029310","Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients",[93],"2023-02-01","2021-09-01",[2903,2904],"Hyperkalemia","Kidney Transplant",[2884],{"trials":2907,"activeCount":102},[],{"intervention":2909,"totalTrials":135,"cells":2910},"Tobramycin once a day",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2919,"NA":2932},{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[],{"trials":2918,"activeCount":102},[],{"trials":2920,"activeCount":102},[2921],{"nctId":2922,"briefTitle":2923,"status":166,"phases":2924,"completion":2925,"start":2926,"enrollment":2927,"conditions":2928,"interventions":2931},"NCT00257790","The Tobramycin Study",[93],"2005-03","2001-09",210,[2929,2930,15],"Neutropenia","Fever",[2909],{"trials":2933,"activeCount":102},[],{"intervention":2935,"totalTrials":135,"cells":2936},"Hylo-comod",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2958},{"trials":2938,"activeCount":102},[],{"trials":2940,"activeCount":102},[],{"trials":2942,"activeCount":102},[],{"trials":2944,"activeCount":102},[],{"trials":2946,"activeCount":102},[2947],{"nctId":2948,"briefTitle":2949,"status":166,"phases":2950,"primaryCompletion":2951,"completion":2952,"start":2953,"enrollment":11,"conditions":2954,"interventions":2957},"NCT03318874","Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction",[93],"2020-04-15","2021-11-17","2017-10-19",[2955,2956],"Dry Eye Syndromes","Meibomian Gland Dysfunction",[2935],{"trials":2959,"activeCount":102},[],{"intervention":2961,"totalTrials":135,"cells":2962},"Antithrombotic Agent",{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2986},{"trials":2964,"activeCount":102},[],{"trials":2966,"activeCount":102},[],{"trials":2968,"activeCount":102},[],{"trials":2970,"activeCount":102},[],{"trials":2972,"activeCount":102},[2973],{"nctId":2974,"briefTitle":2975,"status":915,"phases":2976,"primaryCompletion":2977,"completion":2977,"start":2978,"enrollment":2979,"conditions":2980,"interventions":2985},"NCT03186729","Study of Antithrombotic Treatment After IntraCerebral Haemorrhage",[93],"2024-08-31","2018-07-01",134,[2981,2982,36,2983,2984],"Cerebral Hemorrhage","Intracranial Hemorrhages","Anticoagulant-Induced Bleeding","Secondary Prevention",[2961],{"trials":2987,"activeCount":102},[],{"intervention":2989,"totalTrials":135,"cells":2990},"Antiepileptic drug",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":2999,"NA":3013},{"trials":2992,"activeCount":102},[],{"trials":2994,"activeCount":102},[],{"trials":2996,"activeCount":102},[],{"trials":2998,"activeCount":102},[],{"trials":3000,"activeCount":102},[3001],{"nctId":3002,"briefTitle":3003,"status":220,"phases":3004,"primaryCompletion":3005,"completion":3006,"start":3007,"enrollment":3008,"conditions":3009,"interventions":3012},"NCT00552526","Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy",[93],"2011-01","2013-12","2007-11",60,[3010,3011],"Epilepsy","Mental Retardation",[2989],{"trials":3014,"activeCount":102},[],{"intervention":3016,"totalTrials":135,"cells":3017},"Anakinra 100 mg in 2 ml saline IA",{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3026,"NA":3039},{"trials":3019,"activeCount":102},[],{"trials":3021,"activeCount":102},[],{"trials":3023,"activeCount":102},[],{"trials":3025,"activeCount":102},[],{"trials":3027,"activeCount":102},[3028],{"nctId":3029,"briefTitle":3030,"status":3031,"phases":3032,"primaryCompletion":3033,"completion":3034,"start":3035,"enrollment":102,"conditions":3036,"interventions":3038},"NCT01997138","Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy","WITHDRAWN",[93],"2018-01","2018-09","2016-03",[3037],"Knee Injuries",[3016],{"trials":3040,"activeCount":102},[],{"intervention":3042,"totalTrials":135,"cells":3043},"Bevacizumab",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3052,"NA":3064},{"trials":3045,"activeCount":102},[],{"trials":3047,"activeCount":102},[],{"trials":3049,"activeCount":102},[],{"trials":3051,"activeCount":102},[],{"trials":3053,"activeCount":102},[3054],{"nctId":3055,"briefTitle":3056,"status":166,"phases":3057,"primaryCompletion":416,"completion":416,"start":3058,"enrollment":3059,"conditions":3060,"interventions":3062},"NCT01127360","LUCAS (Lucentis Compared to Avastin Study)",[93],"2009-03",420,[3061],"Exudative Age-related Macular Degeneration",[3042,3063],"Ranibizumab",{"trials":3065,"activeCount":102},[],{"intervention":3063,"totalTrials":135,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3082},{"trials":3069,"activeCount":102},[],{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":102},[],{"trials":3075,"activeCount":102},[],{"trials":3077,"activeCount":102},[3078],{"nctId":3055,"briefTitle":3056,"status":166,"phases":3079,"primaryCompletion":416,"completion":416,"start":3058,"enrollment":3059,"conditions":3080,"interventions":3081},[93],[3061],[3042,3063],{"trials":3083,"activeCount":102},[],{"intervention":3085,"totalTrials":135,"cells":3086},"Racemic adrenaline",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3106},{"trials":3088,"activeCount":102},[],{"trials":3090,"activeCount":102},[],{"trials":3092,"activeCount":102},[],{"trials":3094,"activeCount":102},[],{"trials":3096,"activeCount":102},[3097],{"nctId":3098,"briefTitle":3099,"status":220,"phases":3100,"primaryCompletion":2385,"completion":3006,"start":3101,"enrollment":224,"conditions":3102,"interventions":3104},"NCT00817466","Bronchiolitis All-study, SE-Norway",[93],"2010-01",[3103],"Bronchiolitis",[3085,3105],"Isotonic saline",{"trials":3107,"activeCount":102},[],{"intervention":3105,"totalTrials":135,"cells":3109},{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3116,"PHASE4":3118,"NA":3124},{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"trials":3115,"activeCount":102},[],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[3120],{"nctId":3098,"briefTitle":3099,"status":220,"phases":3121,"primaryCompletion":2385,"completion":3006,"start":3101,"enrollment":224,"conditions":3122,"interventions":3123},[93],[3103],[3085,3105],{"trials":3125,"activeCount":102},[],{"intervention":3127,"totalTrials":135,"cells":3128},"Mycophenolate Mofetil 500 mg Tab",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3135,"PHASE4":3137,"NA":3148},{"trials":3130,"activeCount":102},[],{"trials":3132,"activeCount":102},[],{"trials":3134,"activeCount":102},[],{"trials":3136,"activeCount":102},[],{"trials":3138,"activeCount":102},[3139],{"nctId":3140,"briefTitle":3141,"status":220,"phases":3142,"primaryCompletion":745,"completion":745,"start":3143,"enrollment":1406,"conditions":3144,"interventions":3146},"NCT04207177","Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects",[93],"2019-10-30",[315,3145],"Immune Suppression",[3127,3147],"Tacrolimus",{"trials":3149,"activeCount":102},[],{"intervention":3147,"totalTrials":135,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3158,"PHASE4":3160,"NA":3166},{"trials":3153,"activeCount":102},[],{"trials":3155,"activeCount":102},[],{"trials":3157,"activeCount":102},[],{"trials":3159,"activeCount":102},[],{"trials":3161,"activeCount":102},[3162],{"nctId":3140,"briefTitle":3141,"status":220,"phases":3163,"primaryCompletion":745,"completion":745,"start":3143,"enrollment":1406,"conditions":3164,"interventions":3165},[93],[315,3145],[3127,3147],{"trials":3167,"activeCount":102},[],{"intervention":3169,"totalTrials":135,"cells":3170},"Phenylephrine",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3190},{"trials":3172,"activeCount":102},[],{"trials":3174,"activeCount":102},[],{"trials":3176,"activeCount":102},[],{"trials":3178,"activeCount":102},[],{"trials":3180,"activeCount":102},[3181],{"nctId":3182,"briefTitle":3183,"status":166,"phases":3184,"completion":3185,"start":3186,"enrollment":1463,"conditions":3187,"interventions":3189},"NCT00199784","Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia",[93],"2007-04","2005-06",[3188],"Healthy",[3169],{"trials":3191,"activeCount":102},[],{"intervention":3193,"totalTrials":135,"cells":3194},"1 Ketorolac intraarticular",{"EARLY_PHASE1":3195,"PHASE1":3197,"PHASE2":3199,"PHASE3":3201,"PHASE4":3203,"NA":3211},{"trials":3196,"activeCount":102},[],{"trials":3198,"activeCount":102},[],{"trials":3200,"activeCount":102},[],{"trials":3202,"activeCount":102},[],{"trials":3204,"activeCount":102},[3205],{"nctId":3206,"briefTitle":3207,"status":166,"phases":3208,"primaryCompletion":417,"completion":2067,"start":2245,"enrollment":115,"conditions":3209,"interventions":3210},"NCT00774540","Acute Pain and Inflammation After Surgery",[93],[3037],[3193],{"trials":3212,"activeCount":102},[],{"intervention":3214,"totalTrials":135,"cells":3215},"Morphine 2.5 mg i.v.",{"EARLY_PHASE1":3216,"PHASE1":3218,"PHASE2":3220,"PHASE3":3222,"PHASE4":3224,"NA":3245},{"trials":3217,"activeCount":102},[],{"trials":3219,"activeCount":102},[],{"trials":3221,"activeCount":102},[],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[3226],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3229,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},"NCT05639712","Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial",[93],"2025-05-27","2025-06-27","2022-12-13",1020,[2163,3235],"Affective Symptoms",[3214,3237,3238,3239,3240,3241,3242,3243,3244],"Morphine 5 mg i.v.","Morphine 10 mg i.v.","Oxycodone 2.5 mg i.v.","Oxycodone 5 mg i.v.","Oxycodone 10 mg i.v.","Fentanyl 0.025 mg i.v.","Fentanyl 0.05 mg i.v.","Fentanyl 0.1 mg i.v.",{"trials":3246,"activeCount":102},[],{"intervention":3237,"totalTrials":135,"cells":3248},{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3263},{"trials":3250,"activeCount":102},[],{"trials":3252,"activeCount":102},[],{"trials":3254,"activeCount":102},[],{"trials":3256,"activeCount":102},[],{"trials":3258,"activeCount":102},[3259],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3260,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3261,"interventions":3262},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3264,"activeCount":102},[],{"intervention":3238,"totalTrials":135,"cells":3266},{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3273,"PHASE4":3275,"NA":3281},{"trials":3268,"activeCount":102},[],{"trials":3270,"activeCount":102},[],{"trials":3272,"activeCount":102},[],{"trials":3274,"activeCount":102},[],{"trials":3276,"activeCount":102},[3277],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3278,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3279,"interventions":3280},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3282,"activeCount":102},[],{"intervention":3239,"totalTrials":135,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3293,"NA":3299},{"trials":3286,"activeCount":102},[],{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[],{"trials":3292,"activeCount":102},[],{"trials":3294,"activeCount":102},[3295],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3296,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3297,"interventions":3298},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3300,"activeCount":102},[],{"intervention":3240,"totalTrials":135,"cells":3302},{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3309,"PHASE4":3311,"NA":3317},{"trials":3304,"activeCount":102},[],{"trials":3306,"activeCount":102},[],{"trials":3308,"activeCount":102},[],{"trials":3310,"activeCount":102},[],{"trials":3312,"activeCount":102},[3313],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3314,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3315,"interventions":3316},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3318,"activeCount":102},[],{"intervention":3241,"totalTrials":135,"cells":3320},{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3329,"NA":3335},{"trials":3322,"activeCount":102},[],{"trials":3324,"activeCount":102},[],{"trials":3326,"activeCount":102},[],{"trials":3328,"activeCount":102},[],{"trials":3330,"activeCount":102},[3331],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3332,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3333,"interventions":3334},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3336,"activeCount":102},[],{"intervention":3242,"totalTrials":135,"cells":3338},{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3347,"NA":3353},{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[],{"trials":3344,"activeCount":102},[],{"trials":3346,"activeCount":102},[],{"trials":3348,"activeCount":102},[3349],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3350,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3351,"interventions":3352},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3354,"activeCount":102},[],{"intervention":3243,"totalTrials":135,"cells":3356},{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3363,"PHASE4":3365,"NA":3371},{"trials":3358,"activeCount":102},[],{"trials":3360,"activeCount":102},[],{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":102},[3367],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3368,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3369,"interventions":3370},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3372,"activeCount":102},[],{"intervention":3244,"totalTrials":135,"cells":3374},{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3379,"PHASE3":3381,"PHASE4":3383,"NA":3389},{"trials":3376,"activeCount":102},[],{"trials":3378,"activeCount":102},[],{"trials":3380,"activeCount":102},[],{"trials":3382,"activeCount":102},[],{"trials":3384,"activeCount":102},[3385],{"nctId":3227,"briefTitle":3228,"status":166,"phases":3386,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3387,"interventions":3388},[93],[2163,3235],[3214,3237,3238,3239,3240,3241,3242,3243,3244],{"trials":3390,"activeCount":102},[],{"intervention":3392,"totalTrials":135,"cells":3393},"Onabotulinumtoxin A",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3414},{"trials":3395,"activeCount":102},[],{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[],{"trials":3401,"activeCount":102},[],{"trials":3403,"activeCount":102},[3404],{"nctId":3405,"briefTitle":3406,"status":166,"phases":3407,"primaryCompletion":3408,"completion":3408,"start":3409,"enrollment":373,"conditions":3410,"interventions":3413},"NCT01698138","Prevention of Bladder Dysfunction in Acute Spinal Cord Injury",[93],"2020-12-20","2012-09",[3411,3412],"Spinal Cord Injuries","Urinary Bladder, Overactive",[3392],{"trials":3415,"activeCount":102},[],{"intervention":3417,"totalTrials":135,"cells":3418},"Empagliflozin",{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3440},{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":102},[],{"trials":3424,"activeCount":102},[],{"trials":3426,"activeCount":102},[],{"trials":3428,"activeCount":102},[3429],{"nctId":3430,"briefTitle":3431,"status":166,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":945,"conditions":3435,"interventions":3439},"NCT03157414","Empagliflozin in Renal Transplant Recipients",[93],"2018-06-28","2016-11-07",[3436,3437,3438],"Diabetes Mellitus","Renal Insufficiency","Safety Issues",[3417],{"trials":3441,"activeCount":102},[],{"intervention":3443,"totalTrials":135,"cells":3444},"Naltrexone\u002Fbupropion",{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3451,"PHASE4":3453,"NA":3465},{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[],{"trials":3450,"activeCount":102},[],{"trials":3452,"activeCount":102},[],{"trials":3454,"activeCount":102},[3455],{"nctId":3456,"briefTitle":3457,"status":3031,"phases":3458,"primaryCompletion":3459,"completion":3460,"start":3461,"enrollment":102,"conditions":3462,"interventions":3464},"NCT04399395","Naltrexone\u002FBupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery",[93],"2022-09-30","2022-12-31","2020-11-01",[3463],"Obesity",[3443],{"trials":3466,"activeCount":102},[],{"intervention":3468,"totalTrials":135,"cells":3469},"Same individuals treated with racemic methadone and switched to levomethadone",{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3476,"PHASE4":3478,"NA":3491},{"trials":3471,"activeCount":102},[],{"trials":3473,"activeCount":102},[],{"trials":3475,"activeCount":102},[],{"trials":3477,"activeCount":102},[],{"trials":3479,"activeCount":102},[3480],{"nctId":3481,"briefTitle":3482,"status":220,"phases":3483,"primaryCompletion":3484,"completion":3485,"start":3486,"enrollment":28,"conditions":3487,"interventions":3490},"NCT04254731","Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals",[93],"2018-06-27","2024-07-30","2015-05-07",[3488,1781,3489],"Adverse Drug Effect","Heart Arrhythmia",[3468],{"trials":3492,"activeCount":102},[],{"intervention":3494,"totalTrials":135,"cells":3495},"Omega-3 fatty acids",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3515},{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[],{"trials":3501,"activeCount":102},[],{"trials":3503,"activeCount":102},[],{"trials":3505,"activeCount":102},[3506],{"nctId":3507,"briefTitle":3508,"status":166,"phases":3509,"primaryCompletion":1291,"completion":1291,"start":3510,"enrollment":3511,"conditions":3512,"interventions":3514},"NCT01744067","The Effects of Omega-3 Fatty Acids in Renal Transplantation",[93],"2013-11",132,[3513],"Disorder Related to Renal Transplantation",[3494],{"trials":3516,"activeCount":102},[],{"intervention":3518,"totalTrials":135,"cells":3519},"Docusate natrium and sorbitol",{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3541},{"trials":3521,"activeCount":102},[],{"trials":3523,"activeCount":102},[],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"trials":3529,"activeCount":102},[3530],{"nctId":3531,"briefTitle":3532,"status":166,"phases":3533,"primaryCompletion":3534,"completion":3534,"start":2292,"enrollment":790,"conditions":3535,"interventions":3539},"NCT01879605","Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery",[93],"2009-12",[3536,3537,3538],"Constipation","Ileus","Surgery",[3518,3540],"Bisacodyl",{"trials":3542,"activeCount":102},[],{"intervention":3540,"totalTrials":135,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3559},{"trials":3546,"activeCount":102},[],{"trials":3548,"activeCount":102},[],{"trials":3550,"activeCount":102},[],{"trials":3552,"activeCount":102},[],{"trials":3554,"activeCount":102},[3555],{"nctId":3531,"briefTitle":3532,"status":166,"phases":3556,"primaryCompletion":3534,"completion":3534,"start":2292,"enrollment":790,"conditions":3557,"interventions":3558},[93],[3536,3537,3538],[3518,3540],{"trials":3560,"activeCount":102},[],{"intervention":3562,"totalTrials":135,"cells":3563},"Bleomycin",{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3568,"PHASE3":3570,"PHASE4":3572,"NA":3585},{"trials":3565,"activeCount":102},[],{"trials":3567,"activeCount":102},[],{"trials":3569,"activeCount":102},[],{"trials":3571,"activeCount":102},[],{"trials":3573,"activeCount":102},[3574],{"nctId":3575,"briefTitle":3576,"status":220,"phases":3577,"primaryCompletion":3578,"completion":3579,"start":2630,"enrollment":3580,"conditions":3581,"interventions":3582},"NCT01347294","Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations",[93],"2023-11-30","2025-06-30",135,[1490],[3562,3583,3584],"Fibrovein","Bleomycin + Fibrovein",{"trials":3586,"activeCount":102},[],{"intervention":3583,"totalTrials":135,"cells":3588},{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3595,"PHASE4":3597,"NA":3603},{"trials":3590,"activeCount":102},[],{"trials":3592,"activeCount":102},[],{"trials":3594,"activeCount":102},[],{"trials":3596,"activeCount":102},[],{"trials":3598,"activeCount":102},[3599],{"nctId":3575,"briefTitle":3576,"status":220,"phases":3600,"primaryCompletion":3578,"completion":3579,"start":2630,"enrollment":3580,"conditions":3601,"interventions":3602},[93],[1490],[3562,3583,3584],{"trials":3604,"activeCount":102},[],{"intervention":3584,"totalTrials":135,"cells":3606},{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3621},{"trials":3608,"activeCount":102},[],{"trials":3610,"activeCount":102},[],{"trials":3612,"activeCount":102},[],{"trials":3614,"activeCount":102},[],{"trials":3616,"activeCount":102},[3617],{"nctId":3575,"briefTitle":3576,"status":220,"phases":3618,"primaryCompletion":3578,"completion":3579,"start":2630,"enrollment":3580,"conditions":3619,"interventions":3620},[93],[1490],[3562,3583,3584],{"trials":3622,"activeCount":102},[],{"intervention":3624,"totalTrials":135,"cells":3625},"Propofol",{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3632,"PHASE4":3634,"NA":3646},{"trials":3627,"activeCount":102},[],{"trials":3629,"activeCount":102},[],{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":102},[3636],{"nctId":3637,"briefTitle":3638,"status":166,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":3641,"enrollment":3642,"conditions":3643,"interventions":3645},"NCT01536002","Pharmacokinetics of Propofol in Morbidly Obese Patients",[93],"2014-05-07","2011-06-07",69,[3644],"Obesity, Morbid",[3624],{"trials":3647,"activeCount":102},[],{"intervention":1610,"totalTrials":98,"cells":3649},{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3660,"PHASE4":3673,"NA":3675},{"trials":3651,"activeCount":102},[],{"trials":3653,"activeCount":102},[],{"trials":3655,"activeCount":102},[3656],{"nctId":1602,"briefTitle":1603,"status":166,"phases":3657,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":28,"conditions":3658,"interventions":3659},[91],[1608],[1610,1611,1612,130],{"trials":3661,"activeCount":102},[3662],{"nctId":3663,"briefTitle":3664,"status":166,"phases":3665,"primaryCompletion":2977,"completion":2977,"start":3666,"enrollment":3667,"conditions":3668,"interventions":3671},"NCT04121403","Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)",[92],"2019-10-16",267,[3669,3670],"Relapsing Multiple Sclerosis","Multiple Sclerosis",[1610,3672],"Cladribine",{"trials":3674,"activeCount":102},[],{"trials":3676,"activeCount":102},[],{"intervention":842,"totalTrials":98,"cells":3678},{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3683,"PHASE3":3685,"PHASE4":3702,"NA":3704},{"trials":3680,"activeCount":102},[],{"trials":3682,"activeCount":102},[],{"trials":3684,"activeCount":102},[],{"trials":3686,"activeCount":102},[3687,3698],{"nctId":3688,"briefTitle":3689,"status":166,"phases":3690,"primaryCompletion":3691,"completion":3692,"start":3693,"enrollment":3694,"conditions":3695,"interventions":3697},"NCT05051735","PARASTOP - Paracetamol With Strong Opioids",[92],"2026-02-11","2026-02-18","2021-10-20",204,[3696,15],"Cancer Pain",[842],{"nctId":831,"briefTitle":832,"status":166,"phases":3699,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":3700,"interventions":3701},[92],[838,839],[811,841,842,843,844,845],{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":102},[],{"intervention":3707,"totalTrials":135,"cells":3708},"Rofecoxib",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3727,"NA":3729},{"trials":3710,"activeCount":102},[],{"trials":3712,"activeCount":102},[],{"trials":3714,"activeCount":102},[],{"trials":3716,"activeCount":102},[3717],{"nctId":3718,"briefTitle":3719,"status":915,"phases":3720,"primaryCompletion":3721,"completion":3721,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3726},"NCT00844727","Coxib-inhibition of Duodenal Polyp Growth in FAP",[91,92],"2004-04","2003-09",38,[3725],"Duodenal Polyposis",[3707],{"trials":3728,"activeCount":102},[],{"trials":3730,"activeCount":102},[],{"intervention":3732,"totalTrials":135,"cells":3733},"Butylscopolamine Bromide 20 MG\u002FML",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3740,"PHASE4":3755,"NA":3757},{"trials":3735,"activeCount":102},[],{"trials":3737,"activeCount":102},[],{"trials":3739,"activeCount":102},[],{"trials":3741,"activeCount":102},[3742],{"nctId":3743,"briefTitle":3744,"status":166,"phases":3745,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":3749,"conditions":3750,"interventions":3753},"NCT03961165","BUSCLAB - Buscopan to Prevent Slow Progress in Labor",[92],"2021-08-29","2022-06-16","2019-05-25",250,[3751,3752],"Labor (Obstetrics)--Complications","Labor; Prolonged, First Stage",[3732,3754],"Sodium Chloride 9mg\u002FmL",{"trials":3756,"activeCount":102},[],{"trials":3758,"activeCount":102},[],{"intervention":3754,"totalTrials":135,"cells":3760},{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3773,"NA":3775},{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":102},[],{"trials":3766,"activeCount":102},[],{"trials":3768,"activeCount":102},[3769],{"nctId":3743,"briefTitle":3744,"status":166,"phases":3770,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":3749,"conditions":3771,"interventions":3772},[92],[3751,3752],[3732,3754],{"trials":3774,"activeCount":102},[],{"trials":3776,"activeCount":102},[],{"intervention":3778,"totalTrials":135,"cells":3779},"Dendritic cell immunization",{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3798,"NA":3800},{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[],{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":102},[3788],{"nctId":3789,"briefTitle":3790,"status":220,"phases":3791,"primaryCompletion":3792,"completion":3793,"start":746,"enrollment":3008,"conditions":3794,"interventions":3796},"NCT03548571","Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy",[91,92],"2025-12-01","2026-05-01",[3795],"Glioblastoma",[3778,3797],"Adjuvant temozolomide",{"trials":3799,"activeCount":102},[],{"trials":3801,"activeCount":102},[],{"intervention":3797,"totalTrials":135,"cells":3803},{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3810,"PHASE4":3816,"NA":3818},{"trials":3805,"activeCount":102},[],{"trials":3807,"activeCount":102},[],{"trials":3809,"activeCount":102},[],{"trials":3811,"activeCount":102},[3812],{"nctId":3789,"briefTitle":3790,"status":220,"phases":3813,"primaryCompletion":3792,"completion":3793,"start":746,"enrollment":3008,"conditions":3814,"interventions":3815},[91,92],[3795],[3778,3797],{"trials":3817,"activeCount":102},[],{"trials":3819,"activeCount":102},[],{"intervention":3821,"totalTrials":135,"cells":3822},"Tacrolimus ointment",{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3840,"NA":3842},{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"trials":3828,"activeCount":102},[],{"trials":3830,"activeCount":102},[3831],{"nctId":3832,"briefTitle":3833,"status":166,"phases":3834,"completion":3835,"start":3836,"conditions":3837,"interventions":3839},"NCT00807690","Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo",[92],"2008-01","2005-11",[3838],"Vitiligo",[3821],{"trials":3841,"activeCount":102},[],{"trials":3843,"activeCount":102},[],{"intervention":3845,"totalTrials":135,"cells":3846},"Octagam",{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3853,"PHASE4":3865,"NA":3867},{"trials":3848,"activeCount":102},[],{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":102},[],{"trials":3854,"activeCount":102},[3855],{"nctId":3856,"briefTitle":3857,"status":166,"phases":3858,"primaryCompletion":3859,"completion":3860,"start":3861,"enrollment":3862,"conditions":3863,"interventions":3864},"NCT00430885","Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction",[92],"2009-05","2010-05","2007-02",62,[270],[3845],{"trials":3866,"activeCount":102},[],{"trials":3868,"activeCount":102},[],{"intervention":1857,"totalTrials":135,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3875,"PHASE3":3877,"PHASE4":3883,"NA":3885},{"trials":3872,"activeCount":102},[],{"trials":3874,"activeCount":102},[],{"trials":3876,"activeCount":102},[],{"trials":3878,"activeCount":102},[3879],{"nctId":1846,"briefTitle":1847,"status":166,"phases":3880,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":3881,"interventions":3882},[92],[1853,1854],[1856,1835,1857],{"trials":3884,"activeCount":102},[],{"trials":3886,"activeCount":102},[],{"intervention":3888,"totalTrials":135,"cells":3889},"Baricitinib",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3896,"PHASE4":3910,"NA":3912},{"trials":3891,"activeCount":102},[],{"trials":3893,"activeCount":102},[],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[3898],{"nctId":3899,"briefTitle":3900,"status":915,"phases":3901,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":3905,"conditions":3906,"interventions":3909},"NCT04891133","EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial",[91,92],"2022-12-15","2023-01-23","2021-06-03",290,[3907,3908],"COVID-19","Emerging Infectious Disease",[3888],{"trials":3911,"activeCount":102},[],{"trials":3913,"activeCount":102},[],{"intervention":3915,"totalTrials":135,"cells":3916},"Iron Isomaltoside 1000",{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3921,"PHASE3":3923,"PHASE4":3935,"NA":3937},{"trials":3918,"activeCount":102},[],{"trials":3920,"activeCount":102},[],{"trials":3922,"activeCount":102},[],{"trials":3924,"activeCount":102},[3925],{"nctId":3926,"briefTitle":3927,"status":166,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":3931,"conditions":3932,"interventions":3934},"NCT03662789","Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients",[91,92],"2020-02-27","2018-04-25",102,[3933],"Heart Transplant Recipients",[3915],{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":102},[],{"intervention":3940,"totalTrials":135,"cells":3941},"Cardiac outcomes on treatment with valsartan",{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3948,"PHASE4":3962,"NA":3964},{"trials":3943,"activeCount":102},[],{"trials":3945,"activeCount":102},[],{"trials":3947,"activeCount":102},[],{"trials":3949,"activeCount":102},[3950],{"nctId":3951,"briefTitle":3952,"status":166,"phases":3953,"primaryCompletion":3954,"completion":3955,"start":3956,"enrollment":3957,"conditions":3958,"interventions":3960},"NCT06395194","Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension",[92],"2003-09-05","2003-12-05","1997-09-27",15313,[3959],"Essential Hypertension",[3940,3961],"Cardiac outcomes on treatment with amlodipine",{"trials":3963,"activeCount":102},[],{"trials":3965,"activeCount":102},[],{"intervention":3961,"totalTrials":135,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3980,"NA":3982},{"trials":3969,"activeCount":102},[],{"trials":3971,"activeCount":102},[],{"trials":3973,"activeCount":102},[],{"trials":3975,"activeCount":102},[3976],{"nctId":3951,"briefTitle":3952,"status":166,"phases":3977,"primaryCompletion":3954,"completion":3955,"start":3956,"enrollment":3957,"conditions":3978,"interventions":3979},[92],[3959],[3940,3961],{"trials":3981,"activeCount":102},[],{"trials":3983,"activeCount":102},[],{"intervention":3985,"totalTrials":135,"cells":3986},"Paricalcitol",{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":4004,"NA":4006},{"trials":3988,"activeCount":102},[],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[3995],{"nctId":3996,"briefTitle":3997,"status":166,"phases":3998,"primaryCompletion":1755,"completion":1291,"start":3999,"enrollment":4000,"conditions":4001,"interventions":4003},"NCT01694160","Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria",[92],"2013-01",77,[4002],"Proteinuria",[3985],{"trials":4005,"activeCount":102},[],{"trials":4007,"activeCount":102},[],{"intervention":4009,"totalTrials":135,"cells":4010},"Vancomycin",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4029,"NA":4031},{"trials":4012,"activeCount":102},[],{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[],{"trials":4018,"activeCount":102},[4019],{"nctId":4020,"briefTitle":4021,"status":915,"phases":4022,"primaryCompletion":4023,"completion":4023,"start":4024,"enrollment":4025,"conditions":4026,"interventions":4028},"NCT03796650","Fecal Transplantation for Primary Clostridium Difficile Infection",[92],"2024-04-02","2019-07-17",104,[4027],"Clostridium Difficile Infection",[4009],{"trials":4030,"activeCount":102},[],{"trials":4032,"activeCount":102},[],{"intervention":4034,"totalTrials":135,"cells":4035},"Intravenous injection of Tenecteplase and one dose of placebo",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4042,"PHASE4":4055,"NA":4057},{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":102},[4044],{"nctId":4045,"briefTitle":4046,"status":166,"phases":4047,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4053},"NCT04526951","TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)",[92],"2025-06-20","2020-10-30",81,[4052],"Central Retinal Artery Occlusion",[4034,4054],"One tablet of Acetylsalicylic Acid and one dose of IV placebo",{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"intervention":4054,"totalTrials":135,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4067,"PHASE4":4073,"NA":4075},{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[],{"trials":4068,"activeCount":102},[4069],{"nctId":4045,"briefTitle":4046,"status":166,"phases":4070,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4071,"interventions":4072},[92],[4052],[4034,4054],{"trials":4074,"activeCount":102},[],{"trials":4076,"activeCount":102},[],{"intervention":4078,"totalTrials":135,"cells":4079},"clobetasol propionate 0,05% ointment",{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4097,"NA":4099},{"trials":4081,"activeCount":102},[],{"trials":4083,"activeCount":102},[],{"trials":4085,"activeCount":102},[],{"trials":4087,"activeCount":102},[4088],{"nctId":4089,"briefTitle":4090,"status":166,"phases":4091,"primaryCompletion":4092,"completion":4092,"start":2630,"enrollment":115,"conditions":4093,"interventions":4095},"NCT01282515","Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT",[91,92],"2014-10",[4094],"Genital Lichen Planus",[4078,4096],"hexaminolevulinate",{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"intervention":4096,"totalTrials":135,"cells":4102},{"EARLY_PHASE1":4103,"PHASE1":4105,"PHASE2":4107,"PHASE3":4109,"PHASE4":4115,"NA":4117},{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":102},[4111],{"nctId":4089,"briefTitle":4090,"status":166,"phases":4112,"primaryCompletion":4092,"completion":4092,"start":2630,"enrollment":115,"conditions":4113,"interventions":4114},[91,92],[4094],[4078,4096],{"trials":4116,"activeCount":102},[],{"trials":4118,"activeCount":102},[],{"intervention":4120,"totalTrials":135,"cells":4121},"Tranexamic acid and Tocilizumab",{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4126,"PHASE3":4128,"PHASE4":4140,"NA":4142},{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[],{"trials":4127,"activeCount":102},[],{"trials":4129,"activeCount":102},[4130],{"nctId":4131,"briefTitle":4132,"status":915,"phases":4133,"primaryCompletion":4134,"completion":2901,"start":4135,"enrollment":4136,"conditions":4137,"interventions":4139},"NCT03353259","Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery",[91,92],"2021-02-28","2017-11-28",382,[4138],"Chronic Subdural Hematoma",[4120],{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[],{"intervention":4145,"totalTrials":135,"cells":4146},"Intestinal microbiota therapy",{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4151,"PHASE3":4153,"PHASE4":4164,"NA":4166},{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":102},[4155],{"nctId":4156,"briefTitle":4157,"status":915,"phases":4158,"primaryCompletion":4159,"completion":4159,"start":4160,"enrollment":919,"conditions":4161,"interventions":4162},"NCT02301000","IMT for Primary Clostridium Difficile Infection",[91,92],"2017-11-16","2015-02-22",[4027],[4145,4163],"Metronidazole",{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"intervention":4163,"totalTrials":135,"cells":4169},{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4176,"PHASE4":4182,"NA":4184},{"trials":4171,"activeCount":102},[],{"trials":4173,"activeCount":102},[],{"trials":4175,"activeCount":102},[],{"trials":4177,"activeCount":102},[4178],{"nctId":4156,"briefTitle":4157,"status":915,"phases":4179,"primaryCompletion":4159,"completion":4159,"start":4160,"enrollment":919,"conditions":4180,"interventions":4181},[91,92],[4027],[4145,4163],{"trials":4183,"activeCount":102},[],{"trials":4185,"activeCount":102},[],{"intervention":3672,"totalTrials":135,"cells":4187},{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4194,"PHASE4":4200,"NA":4202},{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[4196],{"nctId":3663,"briefTitle":3664,"status":166,"phases":4197,"primaryCompletion":2977,"completion":2977,"start":3666,"enrollment":3667,"conditions":4198,"interventions":4199},[92],[3669,3670],[1610,3672],{"trials":4201,"activeCount":102},[],{"trials":4203,"activeCount":102},[],{"intervention":4205,"totalTrials":135,"cells":4206},"Hydroxychloroquine",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4229,"NA":4231},{"trials":4208,"activeCount":102},[],{"trials":4210,"activeCount":102},[],{"trials":4212,"activeCount":102},[],{"trials":4214,"activeCount":102},[4215],{"nctId":4216,"briefTitle":4217,"status":220,"phases":4218,"primaryCompletion":4219,"completion":4220,"start":4221,"enrollment":4222,"conditions":4223,"interventions":4227},"NCT04321616","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients",[91,92],"2020-08","2020-11","2020-03-28",700,[4224,4225,4226],"SARS-CoV Infection","COVID 19","Acute Respiratory Distress Syndrome ARDS",[4205,4228],"Remdesivir",{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"intervention":4228,"totalTrials":135,"cells":4234},{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4247,"NA":4249},{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[4243],{"nctId":4216,"briefTitle":4217,"status":220,"phases":4244,"primaryCompletion":4219,"completion":4220,"start":4221,"enrollment":4222,"conditions":4245,"interventions":4246},[91,92],[4224,4225,4226],[4205,4228],{"trials":4248,"activeCount":102},[],{"trials":4250,"activeCount":102},[],{"intervention":843,"totalTrials":135,"cells":4252},{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4259,"PHASE4":4265,"NA":4267},{"trials":4254,"activeCount":102},[],{"trials":4256,"activeCount":102},[],{"trials":4258,"activeCount":102},[],{"trials":4260,"activeCount":102},[4261],{"nctId":831,"briefTitle":832,"status":166,"phases":4262,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":4263,"interventions":4264},[92],[838,839],[811,841,842,843,844,845],{"trials":4266,"activeCount":102},[],{"trials":4268,"activeCount":102},[],{"intervention":845,"totalTrials":135,"cells":4270},{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4277,"PHASE4":4283,"NA":4285},{"trials":4272,"activeCount":102},[],{"trials":4274,"activeCount":102},[],{"trials":4276,"activeCount":102},[],{"trials":4278,"activeCount":102},[4279],{"nctId":831,"briefTitle":832,"status":166,"phases":4280,"primaryCompletion":834,"completion":835,"start":836,"enrollment":823,"conditions":4281,"interventions":4282},[92],[838,839],[811,841,842,843,844,845],{"trials":4284,"activeCount":102},[],{"trials":4286,"activeCount":102},[],{"intervention":4288,"totalTrials":135,"cells":4289},"Biosimilar Infliximab",{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4294,"PHASE3":4296,"PHASE4":4307,"NA":4309},{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[4298],{"nctId":4299,"briefTitle":4300,"status":166,"phases":4301,"primaryCompletion":4302,"completion":4303,"start":4304,"enrollment":1553,"conditions":4305,"interventions":4306},"NCT03704363","BackToBasic: Infliximab in Chronic Low Back Pain and Modic Changes",[92],"2023-07-27","2023-09-29","2018-12-12",[1995],[4288],{"trials":4308,"activeCount":102},[],{"trials":4310,"activeCount":102},[],{"intervention":443,"totalTrials":98,"cells":4312},{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4328,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4314,"activeCount":102},[],{"trials":4316,"activeCount":102},[4317],{"nctId":4318,"briefTitle":4319,"status":220,"phases":4320,"primaryCompletion":4321,"completion":4322,"start":4323,"enrollment":373,"conditions":4324,"interventions":4327},"NCT05056389","Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)",[90],"2023-03-31","2023-06-30","2021-09-17",[4325,4326],"Peritoneal Metastases","Colo-rectal Cancer",[443],{"trials":4329,"activeCount":102},[4330],{"nctId":434,"briefTitle":435,"status":166,"phases":4331,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":4332,"interventions":4333},[91],[441],[443,444,67,445],{"trials":4335,"activeCount":102},[],{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"intervention":176,"totalTrials":98,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[4348,4352],{"nctId":901,"briefTitle":902,"status":166,"phases":4349,"primaryCompletion":904,"completion":905,"start":906,"enrollment":907,"conditions":4350,"interventions":4351},[91],[909,910],[882,176,177],{"nctId":164,"briefTitle":165,"status":166,"phases":4353,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":4354,"interventions":4355},[91],[33,172,173],[155,175,176,177],{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[],{"intervention":177,"totalTrials":98,"cells":4363},{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4378,"PHASE4":4380,"NA":4382},{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[],{"trials":4369,"activeCount":102},[4370,4374],{"nctId":901,"briefTitle":902,"status":166,"phases":4371,"primaryCompletion":904,"completion":905,"start":906,"enrollment":907,"conditions":4372,"interventions":4373},[91],[909,910],[882,176,177],{"nctId":164,"briefTitle":165,"status":166,"phases":4375,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":4376,"interventions":4377},[91],[33,172,173],[155,175,176,177],{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[],{"intervention":4385,"totalTrials":135,"cells":4386},"Nicotinamide riboside",{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4405,"PHASE4":4407,"NA":4409},{"trials":4388,"activeCount":102},[],{"trials":4390,"activeCount":102},[],{"trials":4392,"activeCount":102},[4393],{"nctId":4394,"briefTitle":4395,"status":166,"phases":4396,"primaryCompletion":4397,"completion":4398,"start":4399,"enrollment":4400,"conditions":4401,"interventions":4404},"NCT04110028","Nicotinamide Riboside in Hospitalized Patients",[90,91],"2022-12-01","2023-12-01","2019-10-01",57,[4402,4403],"Inflammation","Acute Illness",[4385],{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[],{"intervention":4412,"totalTrials":135,"cells":4413},"doxorubicin , ifosfamide",{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4415,"activeCount":102},[],{"trials":4417,"activeCount":102},[],{"trials":4419,"activeCount":102},[4420],{"nctId":4421,"briefTitle":4422,"status":220,"phases":4423,"primaryCompletion":2130,"completion":4424,"start":4425,"enrollment":4426,"conditions":4427,"interventions":4429},"NCT00790244","A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall",[91],"2022-10","2007-10",188,[947,4428],"Non Metastatic Disease",[4412,4430,4430,4430],"doxorubicin, ifosfamide",{"trials":4432,"activeCount":102},[],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":102},[],{"intervention":4430,"totalTrials":135,"cells":4438},{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4440,"activeCount":102},[],{"trials":4442,"activeCount":102},[],{"trials":4444,"activeCount":102},[4445],{"nctId":4421,"briefTitle":4422,"status":220,"phases":4446,"primaryCompletion":2130,"completion":4424,"start":4425,"enrollment":4426,"conditions":4447,"interventions":4448},[91],[947,4428],[4412,4430,4430,4430],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":102},[],{"trials":4454,"activeCount":102},[],{"intervention":4456,"totalTrials":135,"cells":4457},"Lactose capsula",{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":102},[],{"trials":4463,"activeCount":102},[4464],{"nctId":4465,"briefTitle":4466,"status":166,"phases":4467,"primaryCompletion":2032,"completion":4468,"start":2103,"enrollment":4469,"conditions":4470,"interventions":4473},"NCT01040429","The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial",[91],"2012-11",120,[4471,4472],"Chronic Fatigue Syndrome","Myalgic Encephalomyelitis",[2683,4456],{"trials":4475,"activeCount":102},[],{"trials":4477,"activeCount":102},[],{"trials":4479,"activeCount":102},[],{"intervention":4481,"totalTrials":135,"cells":4482},"7.2% NaCl in 6% hydroxyethyl starch solution",{"EARLY_PHASE1":4483,"PHASE1":4485,"PHASE2":4487,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4484,"activeCount":102},[],{"trials":4486,"activeCount":102},[],{"trials":4488,"activeCount":102},[4489],{"nctId":4490,"briefTitle":4491,"status":166,"phases":4492,"completion":4493,"start":4494,"enrollment":373,"conditions":4495,"interventions":4497},"NCT00199706","HyperHAES Versus Placebo - Effect on Intracranial Pressure in SAH Patients",[91],"2004-10","2002-04",[4496],"Subarachnoid Hemorrhage",[4481],{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[],{"trials":4503,"activeCount":102},[],{"intervention":4505,"totalTrials":135,"cells":4506},"Dendritic cell vaccine",{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4508,"activeCount":102},[],{"trials":4510,"activeCount":102},[],{"trials":4512,"activeCount":102},[4513],{"nctId":4514,"briefTitle":4515,"status":220,"phases":4516,"primaryCompletion":4517,"completion":4518,"start":4519,"enrollment":747,"conditions":4520,"interventions":4521},"NCT01197625","Vaccine Therapy in Curative Resected Prostate Cancer Patients",[90,91],"2024-09","2025-09","2010-09",[18],[4505],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[],{"intervention":1903,"totalTrials":135,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4540,"PHASE4":4542,"NA":4544},{"trials":4531,"activeCount":102},[],{"trials":4533,"activeCount":102},[],{"trials":4535,"activeCount":102},[4536],{"nctId":1894,"briefTitle":1895,"status":166,"phases":4537,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1317,"conditions":4538,"interventions":4539},[91],[1900,1901],[1903,1885],{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"intervention":4547,"totalTrials":135,"cells":4548},"Docetaxel",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4553,"PHASE3":4564,"PHASE4":4566,"NA":4568},{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"trials":4554,"activeCount":102},[4555],{"nctId":4556,"briefTitle":4557,"status":166,"phases":4558,"primaryCompletion":4468,"completion":4559,"start":4560,"enrollment":4561,"conditions":4562,"interventions":4563},"NCT00248703","Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow",[91],"2022-04","2003-10",1128,[33],[4547],{"trials":4565,"activeCount":102},[],{"trials":4567,"activeCount":102},[],{"trials":4569,"activeCount":102},[],{"intervention":4571,"totalTrials":135,"cells":4572},"Remifentanil+clonidine",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4588,"PHASE4":4590,"NA":4592},{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"trials":4578,"activeCount":102},[4579],{"nctId":4580,"briefTitle":4581,"status":166,"phases":4582,"primaryCompletion":2293,"completion":2293,"start":4583,"enrollment":1488,"conditions":4584,"interventions":4587},"NCT00730054","Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers",[90,91],"2005-02",[1853,4585,4586],"Respiration","Sedation",[4571],{"trials":4589,"activeCount":102},[],{"trials":4591,"activeCount":102},[],{"trials":4593,"activeCount":102},[],{"intervention":4595,"totalTrials":135,"cells":4596},"Intracoronary aotologous stem cell transplantation",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4598,"activeCount":102},[],{"trials":4600,"activeCount":102},[],{"trials":4602,"activeCount":102},[4603],{"nctId":4604,"briefTitle":4605,"status":166,"phases":4606,"completion":4607,"start":3722,"enrollment":1406,"conditions":4608,"interventions":4610},"NCT00199823","Autologous Stem Cell Transplantation in Acute Myocardial Infarction",[91],"2006-05",[4609],"Acute Anterior Wall Myocardial Infarction",[4595],{"trials":4612,"activeCount":102},[],{"trials":4614,"activeCount":102},[],{"trials":4616,"activeCount":102},[],{"intervention":4618,"totalTrials":135,"cells":4619},"Dendritic Cells (DC) malignant melanoma",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4635,"PHASE4":4637,"NA":4639},{"trials":4621,"activeCount":102},[],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[4626],{"nctId":4627,"briefTitle":4628,"status":166,"phases":4629,"primaryCompletion":4630,"completion":1291,"start":4631,"enrollment":4632,"conditions":4633,"interventions":4634},"NCT01278940","Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma",[90,91],"2006-02","2002-03",31,[191],[4618],{"trials":4636,"activeCount":102},[],{"trials":4638,"activeCount":102},[],{"trials":4640,"activeCount":102},[],{"intervention":1611,"totalTrials":135,"cells":4642},{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4653,"PHASE4":4655,"NA":4657},{"trials":4644,"activeCount":102},[],{"trials":4646,"activeCount":102},[],{"trials":4648,"activeCount":102},[4649],{"nctId":1602,"briefTitle":1603,"status":166,"phases":4650,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":28,"conditions":4651,"interventions":4652},[91],[1608],[1610,1611,1612,130],{"trials":4654,"activeCount":102},[],{"trials":4656,"activeCount":102},[],{"trials":4658,"activeCount":102},[],{"intervention":1612,"totalTrials":135,"cells":4660},{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4671,"PHASE4":4673,"NA":4675},{"trials":4662,"activeCount":102},[],{"trials":4664,"activeCount":102},[],{"trials":4666,"activeCount":102},[4667],{"nctId":1602,"briefTitle":1603,"status":166,"phases":4668,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":28,"conditions":4669,"interventions":4670},[91],[1608],[1610,1611,1612,130],{"trials":4672,"activeCount":102},[],{"trials":4674,"activeCount":102},[],{"trials":4676,"activeCount":102},[],{"intervention":4678,"totalTrials":135,"cells":4679},"Erlotinib",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4684,"PHASE3":4695,"PHASE4":4697,"NA":4699},{"trials":4681,"activeCount":102},[],{"trials":4683,"activeCount":102},[],{"trials":4685,"activeCount":102},[4686],{"nctId":4687,"briefTitle":4688,"status":915,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":4692,"conditions":4693,"interventions":4694},"NCT02714530","Thoracal Radiotherapy and Tarceva",[91],"2020-12-30","2014-04-01",118,[15],[4678],{"trials":4696,"activeCount":102},[],{"trials":4698,"activeCount":102},[],{"trials":4700,"activeCount":102},[],{"intervention":4702,"totalTrials":135,"cells":4703},"Intravenous iron isomaltoside",{"EARLY_PHASE1":4704,"PHASE1":4706,"PHASE2":4708,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4705,"activeCount":102},[],{"trials":4707,"activeCount":102},[],{"trials":4709,"activeCount":102},[4710],{"nctId":4711,"briefTitle":4712,"status":166,"phases":4713,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":4716,"conditions":4717,"interventions":4720},"NCT04206228","Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis",[91],"2022-02-15","2020-01-13",149,[4718,4719],"Severe Aortic Stenosis","Iron-deficiency",[4702],{"trials":4722,"activeCount":102},[],{"trials":4724,"activeCount":102},[],{"trials":4726,"activeCount":102},[],{"intervention":4728,"totalTrials":135,"cells":4729},"Anaerobically Cultivated Human Intestinal Microbiota",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4731,"activeCount":102},[],{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[4736],{"nctId":4737,"briefTitle":4738,"status":166,"phases":4739,"primaryCompletion":4740,"completion":4741,"start":4742,"enrollment":28,"conditions":4743,"interventions":4745},"NCT03444220","Gut Microbiota Transplantation in Systemic Sclerosis",[90,91],"2018-05-18","2018-10-15","2018-01-18",[4744],"Scleroderma, Systemic",[4728,4746],"Anaerobically Cultivated medium",{"trials":4748,"activeCount":102},[],{"trials":4750,"activeCount":102},[],{"trials":4752,"activeCount":102},[],{"intervention":4746,"totalTrials":135,"cells":4754},{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4759,"PHASE3":4765,"PHASE4":4767,"NA":4769},{"trials":4756,"activeCount":102},[],{"trials":4758,"activeCount":102},[],{"trials":4760,"activeCount":102},[4761],{"nctId":4737,"briefTitle":4738,"status":166,"phases":4762,"primaryCompletion":4740,"completion":4741,"start":4742,"enrollment":28,"conditions":4763,"interventions":4764},[90,91],[4744],[4728,4746],{"trials":4766,"activeCount":102},[],{"trials":4768,"activeCount":102},[],{"trials":4770,"activeCount":102},[],{"intervention":4772,"totalTrials":135,"cells":4773},"Propranolol",{"EARLY_PHASE1":4774,"PHASE1":4776,"PHASE2":4778,"PHASE3":4789,"PHASE4":4791,"NA":4793},{"trials":4775,"activeCount":102},[],{"trials":4777,"activeCount":102},[],{"trials":4779,"activeCount":102},[4780],{"nctId":4781,"briefTitle":4782,"status":166,"phases":4783,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":115,"conditions":4787,"interventions":4788},"NCT05679193","Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence",[91],"2023-11-28","2024-01-27","2023-01-02",[18],[4772],{"trials":4790,"activeCount":102},[],{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[],{"intervention":4796,"totalTrials":135,"cells":4797},"Radiation plus erlotinib",{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4814,"PHASE4":4816,"NA":4818},{"trials":4799,"activeCount":102},[],{"trials":4801,"activeCount":102},[],{"trials":4803,"activeCount":102},[4804],{"nctId":4805,"briefTitle":4806,"status":915,"phases":4807,"primaryCompletion":4808,"completion":4809,"start":4810,"enrollment":4811,"conditions":4812,"interventions":4813},"NCT01518621","Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer",[91],"2017-12-10","2018-12-10","2012-05",25,[15],[4796],{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":102},[],{"trials":4819,"activeCount":102},[],{"intervention":4821,"totalTrials":135,"cells":4822},"riboflavin with hydroxypropyl methylcellulose",{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4824,"activeCount":102},[],{"trials":4826,"activeCount":102},[],{"trials":4828,"activeCount":102},[4829],{"nctId":4830,"briefTitle":4831,"status":220,"phases":4832,"primaryCompletion":4833,"completion":4833,"start":4834,"enrollment":115,"conditions":4835,"interventions":4838},"NCT02883478","Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL).",[90,91],"2016-08","2012-08",[4836,4837],"Keratoconus","Corneal Ectasia",[4821],{"trials":4840,"activeCount":102},[],{"trials":4842,"activeCount":102},[],{"trials":4844,"activeCount":102},[],{"intervention":4846,"totalTrials":135,"cells":4847},"90Y-ibritumomab tiuxetan",{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4852,"PHASE3":4863,"PHASE4":4865,"NA":4867},{"trials":4849,"activeCount":102},[],{"trials":4851,"activeCount":102},[],{"trials":4853,"activeCount":102},[4854],{"nctId":4855,"briefTitle":4856,"status":166,"phases":4857,"primaryCompletion":4858,"completion":4858,"start":3836,"enrollment":4859,"conditions":4860,"interventions":4862},"NCT00514475","Zevalin-BEAM\u002FBEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma",[91],"2009-06",160,[4861],"Mantle Cell Lymphoma",[4846],{"trials":4864,"activeCount":102},[],{"trials":4866,"activeCount":102},[],{"trials":4868,"activeCount":102},[],{"intervention":4870,"totalTrials":135,"cells":4871},"AZD9291",{"EARLY_PHASE1":4872,"PHASE1":4874,"PHASE2":4876,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4873,"activeCount":102},[],{"trials":4875,"activeCount":102},[],{"trials":4877,"activeCount":102},[4878],{"nctId":4879,"briefTitle":4880,"status":220,"phases":4881,"primaryCompletion":4882,"completion":4883,"start":4884,"enrollment":4885,"conditions":4886,"interventions":4889},"NCT02504346","AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies",[91],"2023-06-01","2023-06","2015-08",200,[4887,4888],"Lung Cancer","Targeted Therapy",[4870],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":102},[],{"trials":4895,"activeCount":102},[],{"intervention":4897,"totalTrials":135,"cells":4898},"Tocilizumab 280 mg",{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4903,"PHASE3":4913,"PHASE4":4915,"NA":4917},{"trials":4900,"activeCount":102},[],{"trials":4902,"activeCount":102},[],{"trials":4904,"activeCount":102},[4905],{"nctId":4906,"briefTitle":4907,"status":166,"phases":4908,"primaryCompletion":3510,"completion":4909,"start":2630,"enrollment":4469,"conditions":4910,"interventions":4911},"NCT01491074","Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction",[91],"2014-04",[271],[4897,4912],"NaCl 0.9% 100 ml",{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":102},[],{"trials":4918,"activeCount":102},[],{"intervention":4912,"totalTrials":135,"cells":4920},{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4922,"activeCount":102},[],{"trials":4924,"activeCount":102},[],{"trials":4926,"activeCount":102},[4927],{"nctId":4906,"briefTitle":4907,"status":166,"phases":4928,"primaryCompletion":3510,"completion":4909,"start":2630,"enrollment":4469,"conditions":4929,"interventions":4930},[91],[271],[4897,4912],{"trials":4932,"activeCount":102},[],{"trials":4934,"activeCount":102},[],{"trials":4936,"activeCount":102},[],{"intervention":4938,"totalTrials":135,"cells":4939},"2nd line chemotherapy",{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4944,"PHASE3":4956,"PHASE4":4958,"NA":4960},{"trials":4941,"activeCount":102},[],{"trials":4943,"activeCount":102},[],{"trials":4945,"activeCount":102},[4946],{"nctId":4947,"briefTitle":4948,"status":4949,"phases":4950,"primaryCompletion":4951,"completion":4952,"start":4953,"enrollment":3862,"conditions":4954,"interventions":4955},"NCT04840186","EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden","SUSPENDED",[91],"2024-12-01","2026-03","2021-03-23",[338,27],[4938],{"trials":4957,"activeCount":102},[],{"trials":4959,"activeCount":102},[],{"trials":4961,"activeCount":102},[],{"intervention":2058,"totalTrials":135,"cells":4963},{"EARLY_PHASE1":4964,"PHASE1":4966,"PHASE2":4968,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4965,"activeCount":102},[],{"trials":4967,"activeCount":102},[],{"trials":4969,"activeCount":102},[4970],{"nctId":2049,"briefTitle":2050,"status":220,"phases":4971,"primaryCompletion":2052,"completion":2053,"start":2054,"enrollment":147,"conditions":4972,"interventions":4973},[91],[2056],[2040,2058],{"trials":4975,"activeCount":102},[],{"trials":4977,"activeCount":102},[],{"trials":4979,"activeCount":102},[],{"intervention":4981,"totalTrials":135,"cells":4982},"Capecitabine",{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4987,"PHASE3":4998,"PHASE4":5000,"NA":5002},{"trials":4984,"activeCount":102},[],{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[4989],{"nctId":4990,"briefTitle":4991,"status":166,"phases":4992,"primaryCompletion":4993,"completion":2675,"start":1618,"enrollment":4994,"conditions":4995,"interventions":4997},"NCT02978612","Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III",[91],"2022-11",170,[4996],"Colon Cancer",[4981],{"trials":4999,"activeCount":102},[],{"trials":5001,"activeCount":102},[],{"trials":5003,"activeCount":102},[],{"intervention":5005,"totalTrials":135,"cells":5006},"Apremilast",{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5011,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5008,"activeCount":102},[],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":102},[5013],{"nctId":5014,"briefTitle":5015,"status":220,"phases":5016,"primaryCompletion":5017,"completion":5018,"start":5019,"enrollment":5020,"conditions":5021,"interventions":5024},"NCT03656666","The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus",[91],"2022-11-30","2023-12-31","2019-09-24",42,[5022,5023],"Lichen Planus of Vulva","Female Genital Disease",[5005],{"trials":5026,"activeCount":102},[],{"trials":5028,"activeCount":102},[],{"trials":5030,"activeCount":102},[],{"intervention":5032,"totalTrials":135,"cells":5033},"Theophylline",{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5038,"PHASE3":5049,"PHASE4":5051,"NA":5053},{"trials":5035,"activeCount":102},[],{"trials":5037,"activeCount":102},[],{"trials":5039,"activeCount":102},[5040],{"nctId":5041,"briefTitle":5042,"status":166,"phases":5043,"primaryCompletion":5044,"completion":5044,"start":5045,"enrollment":28,"conditions":5046,"interventions":5048},"NCT05717049","Theophylline Effects in the Fontan Circulation",[91],"2023-09-15","2023-02-09",[5047],"Congenital Heart Disease",[5032],{"trials":5050,"activeCount":102},[],{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[],{"intervention":5056,"totalTrials":135,"cells":5057},"Teriflunomide Oral",{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5073,"PHASE4":5075,"NA":5077},{"trials":5059,"activeCount":102},[],{"trials":5061,"activeCount":102},[],{"trials":5063,"activeCount":102},[5064],{"nctId":5065,"briefTitle":5066,"status":166,"phases":5067,"primaryCompletion":5068,"completion":5018,"start":5069,"enrollment":19,"conditions":5070,"interventions":5072},"NCT04806737","Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease",[90,91],"2022-10-15","2021-04-16",[5071],"Celiac Disease",[5056],{"trials":5074,"activeCount":102},[],{"trials":5076,"activeCount":102},[],{"trials":5078,"activeCount":102},[],{"intervention":5080,"totalTrials":135,"cells":5081},"Tocilizumab",{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5099,"PHASE4":5101,"NA":5103},{"trials":5083,"activeCount":102},[],{"trials":5085,"activeCount":102},[],{"trials":5087,"activeCount":102},[5088],{"nctId":5089,"briefTitle":5090,"status":166,"phases":5091,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":4885,"conditions":5095,"interventions":5097},"NCT03004703","ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial",[91],"2020-02-19","2021-02-10","2017-03-16",[5096,2835],"Coronary Disease",[5080,5098],"Sodium chloride 0.9%",{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[],{"intervention":5098,"totalTrials":135,"cells":5106},{"EARLY_PHASE1":5107,"PHASE1":5109,"PHASE2":5111,"PHASE3":5117,"PHASE4":5119,"NA":5121},{"trials":5108,"activeCount":102},[],{"trials":5110,"activeCount":102},[],{"trials":5112,"activeCount":102},[5113],{"nctId":5089,"briefTitle":5090,"status":166,"phases":5114,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":4885,"conditions":5115,"interventions":5116},[91],[5096,2835],[5080,5098],{"trials":5118,"activeCount":102},[],{"trials":5120,"activeCount":102},[],{"trials":5122,"activeCount":102},[],{"intervention":444,"totalTrials":135,"cells":5124},{"EARLY_PHASE1":5125,"PHASE1":5127,"PHASE2":5129,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5126,"activeCount":102},[],{"trials":5128,"activeCount":102},[],{"trials":5130,"activeCount":102},[5131],{"nctId":434,"briefTitle":435,"status":166,"phases":5132,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":5133,"interventions":5134},[91],[441],[443,444,67,445],{"trials":5136,"activeCount":102},[],{"trials":5138,"activeCount":102},[],{"trials":5140,"activeCount":102},[],{"intervention":445,"totalTrials":135,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5153,"PHASE4":5155,"NA":5157},{"trials":5144,"activeCount":102},[],{"trials":5146,"activeCount":102},[],{"trials":5148,"activeCount":102},[5149],{"nctId":434,"briefTitle":435,"status":166,"phases":5150,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":5151,"interventions":5152},[91],[441],[443,444,67,445],{"trials":5154,"activeCount":102},[],{"trials":5156,"activeCount":102},[],{"trials":5158,"activeCount":102},[],{"intervention":5160,"totalTrials":135,"cells":5161},"BM7PE",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5178,"PHASE4":5180,"NA":5182},{"trials":5163,"activeCount":102},[],{"trials":5165,"activeCount":102},[],{"trials":5167,"activeCount":102},[5168],{"nctId":5169,"briefTitle":5170,"status":915,"phases":5171,"primaryCompletion":5172,"completion":5173,"start":5174,"enrollment":22,"conditions":5175,"interventions":5177},"NCT04550897","A Phase I\u002FII Study With BM7PE Immunotoxin in Colorectal Cancer Patients",[90,91],"2024-06-30","2025-05-06","2020-08-31",[5176],"Colorectal Cancer Metastatic",[5160],{"trials":5179,"activeCount":102},[],{"trials":5181,"activeCount":102},[],{"trials":5183,"activeCount":102},[],{"intervention":5185,"totalTrials":135,"cells":5186},"GV1001",{"EARLY_PHASE1":5187,"PHASE1":5189,"PHASE2":5191,"PHASE3":5200,"PHASE4":5202,"NA":5204},{"trials":5188,"activeCount":102},[],{"trials":5190,"activeCount":102},[],{"trials":5192,"activeCount":102},[5193],{"nctId":5194,"briefTitle":5195,"status":166,"phases":5196,"primaryCompletion":2267,"completion":3409,"start":5197,"conditions":5198,"interventions":5199},"NCT01247623","Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma",[90,91],"2005-01",[191],[5185],{"trials":5201,"activeCount":102},[],{"trials":5203,"activeCount":102},[],{"trials":5205,"activeCount":102},[],{"intervention":5207,"totalTrials":135,"cells":5208},"Semaglutide",{"EARLY_PHASE1":5209,"PHASE1":5211,"PHASE2":5213,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5210,"activeCount":102},[],{"trials":5212,"activeCount":102},[],{"trials":5214,"activeCount":102},[5215],{"nctId":5216,"briefTitle":5217,"status":220,"phases":5218,"primaryCompletion":5219,"completion":5219,"start":5220,"enrollment":4469,"conditions":5221,"interventions":5223},"NCT03659682","GLP1R in Parkinson's Disease",[91],"2024-12-31","2019-01-02",[5222],"Parkinson Disease",[5207],{"trials":5225,"activeCount":102},[],{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"intervention":5231,"totalTrials":135,"cells":5232},"7.5% NaCl in 6% dextran 70 solution",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5251,"PHASE4":5253,"NA":5255},{"trials":5234,"activeCount":102},[],{"trials":5236,"activeCount":102},[],{"trials":5238,"activeCount":102},[5239],{"nctId":5240,"briefTitle":5241,"status":166,"phases":5242,"primaryCompletion":5243,"completion":4583,"start":5244,"enrollment":22,"conditions":5245,"interventions":5250},"NCT00199771","Hypertonic Saline Dextran in Pediatric Cardiac Surgery",[91],"2004-12","2003-06",[5246,5247,5248,5249],"Heart Defects, Congenital","Transposition of Great Vessels","Heart Septal Defects, Ventricular","Endocardial Cushion Defects",[5231],{"trials":5252,"activeCount":102},[],{"trials":5254,"activeCount":102},[],{"trials":5256,"activeCount":102},[],{"intervention":5258,"totalTrials":135,"cells":5259},"Radiotherapy, rituximab and DC",{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5264,"PHASE3":5273,"PHASE4":5275,"NA":5277},{"trials":5261,"activeCount":102},[],{"trials":5263,"activeCount":102},[],{"trials":5265,"activeCount":102},[5266],{"nctId":5267,"briefTitle":5268,"status":166,"phases":5269,"primaryCompletion":4092,"completion":4092,"start":5270,"enrollment":22,"conditions":5271,"interventions":5272},"NCT01926639","Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma",[91],"2009-10",[1608],[5258],{"trials":5274,"activeCount":102},[],{"trials":5276,"activeCount":102},[],{"trials":5278,"activeCount":102},[],{"intervention":5280,"totalTrials":135,"cells":5281},"GAD-alum",{"EARLY_PHASE1":5282,"PHASE1":5284,"PHASE2":5286,"PHASE3":5297,"PHASE4":5299,"NA":5301},{"trials":5283,"activeCount":102},[],{"trials":5285,"activeCount":102},[],{"trials":5287,"activeCount":102},[5288],{"nctId":5289,"briefTitle":5290,"status":915,"phases":5291,"primaryCompletion":3999,"completion":3999,"start":3005,"enrollment":2746,"conditions":5292,"interventions":5296},"NCT01129232","Diabetes Virus Detection Project, Intervention With GAD-alum",[91],[5293,5294,5295],"Diabetes, Type I","Enterovirus Infections","Autoimmunity",[5280],{"trials":5298,"activeCount":102},[],{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[],{"intervention":5304,"totalTrials":135,"cells":5305},"Adoptive Cell Therapy",{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5320,"PHASE4":5322,"NA":5324},{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[],{"trials":5311,"activeCount":102},[5312],{"nctId":5313,"briefTitle":5314,"status":915,"phases":5315,"primaryCompletion":5316,"completion":5316,"start":5317,"enrollment":135,"conditions":5318,"interventions":5319},"NCT03431311","T Cell Receptor Based Therapy of Metastatic Colorectal Cancer",[90,91],"2019-06-12","2018-03-08",[27],[5304],{"trials":5321,"activeCount":102},[],{"trials":5323,"activeCount":102},[],{"trials":5325,"activeCount":102},[],{"intervention":5327,"totalTrials":135,"cells":5328},"Levothyroxin",{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5333,"PHASE3":5347,"PHASE4":5349,"NA":5351},{"trials":5330,"activeCount":102},[],{"trials":5332,"activeCount":102},[],{"trials":5334,"activeCount":102},[5335],{"nctId":5336,"briefTitle":5337,"status":166,"phases":5338,"primaryCompletion":5339,"completion":5339,"start":5340,"enrollment":3642,"conditions":5341,"interventions":5345},"NCT03627611","Identification of Non-responders to Levothyroxine Therapy",[91],"2020-06-22","2018-08-14",[5342,5343,5344],"Hypothyroidism","Biomarkers","Endocrine System Diseases",[5327,5346],"Liothyronine",{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[],{"trials":5352,"activeCount":102},[],{"intervention":5346,"totalTrials":135,"cells":5354},{"EARLY_PHASE1":5355,"PHASE1":5357,"PHASE2":5359,"PHASE3":5365,"PHASE4":5367,"NA":5369},{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"trials":5360,"activeCount":102},[5361],{"nctId":5336,"briefTitle":5337,"status":166,"phases":5362,"primaryCompletion":5339,"completion":5339,"start":5340,"enrollment":3642,"conditions":5363,"interventions":5364},[91],[5342,5343,5344],[5327,5346],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[],{"trials":5370,"activeCount":102},[],{"intervention":5372,"totalTrials":135,"cells":5373},"EMA-approved ATI based targeted therapy",{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5375,"activeCount":102},[],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[5380],{"nctId":5381,"briefTitle":5382,"status":166,"phases":5383,"primaryCompletion":5384,"completion":5384,"start":5385,"enrollment":404,"conditions":5386,"interventions":5388},"NCT02142036","N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy",[91],"2018-08","2014-05",[5387],"Metastatic Cancer",[5372],{"trials":5390,"activeCount":102},[],{"trials":5392,"activeCount":102},[],{"trials":5394,"activeCount":102},[],{"intervention":1913,"totalTrials":135,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5407,"PHASE4":5409,"NA":5411},{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":102},[5403],{"nctId":1905,"briefTitle":1906,"status":166,"phases":5404,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":115,"conditions":5405,"interventions":5406},[91],[1911],[1913,1885],{"trials":5408,"activeCount":102},[],{"trials":5410,"activeCount":102},[],{"trials":5412,"activeCount":102},[],{"intervention":5414,"totalTrials":135,"cells":5415},"Isatuximab, bortezomib, lenalidomide, dexamethason",{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5430,"PHASE4":5432,"NA":5434},{"trials":5417,"activeCount":102},[],{"trials":5419,"activeCount":102},[],{"trials":5421,"activeCount":102},[5422],{"nctId":5423,"briefTitle":5424,"status":166,"phases":5425,"primaryCompletion":2977,"completion":2977,"start":5426,"enrollment":5427,"conditions":5428,"interventions":5429},"NCT04939844","REST - Replacing Steroids in the Transplant Ineligble",[91],"2021-06-29",51,[482],[5414],{"trials":5431,"activeCount":102},[],{"trials":5433,"activeCount":102},[],{"trials":5435,"activeCount":102},[],{"intervention":5437,"totalTrials":135,"cells":5438},"\"ACHIM\" as solute",{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5443,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5440,"activeCount":102},[],{"trials":5442,"activeCount":102},[],{"trials":5444,"activeCount":102},[5445],{"nctId":5446,"briefTitle":5447,"status":166,"phases":5448,"primaryCompletion":5449,"completion":5449,"start":5450,"enrollment":419,"conditions":5451,"interventions":5453},"NCT04300426","Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)",[91],"2022-06-27","2020-09-24",[5452],"Systemic Sclerosis",[5437],{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"intervention":5461,"totalTrials":135,"cells":5462},"OSU 6162",{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5478,"PHASE4":5480,"NA":5482},{"trials":5464,"activeCount":102},[],{"trials":5466,"activeCount":102},[],{"trials":5468,"activeCount":102},[5469],{"nctId":5470,"briefTitle":5471,"status":166,"phases":5472,"primaryCompletion":5473,"completion":5473,"start":5474,"enrollment":1406,"conditions":5475,"interventions":5477},"NCT03209830","Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage",[91],"2019-09-13","2017-09-05",[5476],"Aneurysmal Subarachnoid Hemorrhage",[5461],{"trials":5479,"activeCount":102},[],{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"intervention":5485,"totalTrials":135,"cells":5486},"Dendritic Cells (DC) prostate",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5502,"PHASE4":5504,"NA":5506},{"trials":5488,"activeCount":102},[],{"trials":5490,"activeCount":102},[],{"trials":5492,"activeCount":102},[5493],{"nctId":5494,"briefTitle":5495,"status":166,"phases":5496,"primaryCompletion":5497,"completion":5498,"start":5499,"conditions":5500,"interventions":5501},"NCT01278914","Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer",[90,91],"2004-08-10","2006-07","2002-02-01",[18],[5485],{"trials":5503,"activeCount":102},[],{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":102},[],{"intervention":5509,"totalTrials":135,"cells":5510},"Metformin",{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5512,"activeCount":102},[],{"trials":5514,"activeCount":102},[],{"trials":5516,"activeCount":102},[5517],{"nctId":5518,"briefTitle":5519,"status":166,"phases":5520,"primaryCompletion":5521,"completion":5522,"start":5523,"enrollment":9,"conditions":5524,"interventions":5526},"NCT04275713","Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC",[91],"2024-06-11","2024-11-08","2020-05-22",[5525],"Cervical Cancer",[5509,5527],"Cisplatin",{"trials":5529,"activeCount":102},[],{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[],{"intervention":5527,"totalTrials":135,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":102},[],{"trials":5541,"activeCount":102},[5542],{"nctId":5518,"briefTitle":5519,"status":166,"phases":5543,"primaryCompletion":5521,"completion":5522,"start":5523,"enrollment":9,"conditions":5544,"interventions":5545},[91],[5525],[5509,5527],{"trials":5547,"activeCount":102},[],{"trials":5549,"activeCount":102},[],{"trials":5551,"activeCount":102},[],{"intervention":5553,"totalTrials":135,"cells":5554},"Omega 3 fatty acids",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5559,"PHASE3":5573,"PHASE4":5575,"NA":5577},{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[],{"trials":5560,"activeCount":102},[5561],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5564,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5566,"interventions":5567},"NCT00455416","Dietary Intervention in Follicular Lymphoma",[91],"2009-04",[1608],[5553,5568,5569,5570,5571,5572],"Selenium (L-Selenomethionine),","Garlic extract","Pomegranate juice","Grape juice","Green Tea",{"trials":5574,"activeCount":102},[],{"trials":5576,"activeCount":102},[],{"trials":5578,"activeCount":102},[],{"intervention":5568,"totalTrials":135,"cells":5580},{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5585,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5582,"activeCount":102},[],{"trials":5584,"activeCount":102},[],{"trials":5586,"activeCount":102},[5587],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5588,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5589,"interventions":5590},[91],[1608],[5553,5568,5569,5570,5571,5572],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[],{"intervention":5569,"totalTrials":135,"cells":5598},{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5603,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5600,"activeCount":102},[],{"trials":5602,"activeCount":102},[],{"trials":5604,"activeCount":102},[5605],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5606,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5607,"interventions":5608},[91],[1608],[5553,5568,5569,5570,5571,5572],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[],{"trials":5614,"activeCount":102},[],{"intervention":5570,"totalTrials":135,"cells":5616},{"EARLY_PHASE1":5617,"PHASE1":5619,"PHASE2":5621,"PHASE3":5627,"PHASE4":5629,"NA":5631},{"trials":5618,"activeCount":102},[],{"trials":5620,"activeCount":102},[],{"trials":5622,"activeCount":102},[5623],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5624,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5625,"interventions":5626},[91],[1608],[5553,5568,5569,5570,5571,5572],{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[],{"intervention":5571,"totalTrials":135,"cells":5634},{"EARLY_PHASE1":5635,"PHASE1":5637,"PHASE2":5639,"PHASE3":5645,"PHASE4":5647,"NA":5649},{"trials":5636,"activeCount":102},[],{"trials":5638,"activeCount":102},[],{"trials":5640,"activeCount":102},[5641],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5642,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5643,"interventions":5644},[91],[1608],[5553,5568,5569,5570,5571,5572],{"trials":5646,"activeCount":102},[],{"trials":5648,"activeCount":102},[],{"trials":5650,"activeCount":102},[],{"intervention":5572,"totalTrials":135,"cells":5652},{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5663,"PHASE4":5665,"NA":5667},{"trials":5654,"activeCount":102},[],{"trials":5656,"activeCount":102},[],{"trials":5658,"activeCount":102},[5659],{"nctId":5562,"briefTitle":5563,"status":220,"phases":5660,"primaryCompletion":5565,"completion":3534,"start":3185,"enrollment":790,"conditions":5661,"interventions":5662},[91],[1608],[5553,5568,5569,5570,5571,5572],{"trials":5664,"activeCount":102},[],{"trials":5666,"activeCount":102},[],{"trials":5668,"activeCount":102},[],{"intervention":5670,"totalTrials":135,"cells":5671},"Gentamicin Sulfate",{"EARLY_PHASE1":5672,"PHASE1":5674,"PHASE2":5676,"PHASE3":5688,"PHASE4":5690,"NA":5692},{"trials":5673,"activeCount":102},[],{"trials":5675,"activeCount":102},[],{"trials":5677,"activeCount":102},[5678],{"nctId":5679,"briefTitle":5680,"status":166,"phases":5681,"primaryCompletion":5682,"completion":5683,"start":2504,"enrollment":5684,"conditions":5685,"interventions":5687},"NCT04644627","Topical Gentamicin Nonsense Suppression Therapy of EB",[90,91],"2022-01-11","2022-05-01",4,[5686],"Epidermolysis Bullosa",[5670],{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[],{"trials":5693,"activeCount":102},[],{"intervention":5695,"totalTrials":135,"cells":5696},"Mablet 360 mg",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5698,"activeCount":102},[],{"trials":5700,"activeCount":102},[],{"trials":5702,"activeCount":102},[5703],{"nctId":5704,"briefTitle":5705,"status":220,"phases":5706,"primaryCompletion":5707,"completion":5707,"start":5708,"enrollment":115,"conditions":5709,"interventions":5712},"NCT04382157","Magnesium Replacement and Hyperglycemia After Kidney Transplantation",[90,91],"2022-08-31","2020-02-25",[5710,5711],"Hypomagnesemia","Kidney Transplantation",[5695],{"trials":5714,"activeCount":102},[],{"trials":5716,"activeCount":102},[],{"trials":5718,"activeCount":102},[],{"intervention":5720,"totalTrials":135,"cells":5721},"Pivmecillinamhydrochlorid",{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5723,"activeCount":102},[],{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[5728],{"nctId":5729,"briefTitle":5730,"status":915,"phases":5731,"primaryCompletion":2337,"completion":5732,"start":5733,"enrollment":373,"conditions":5734,"interventions":5737},"NCT02083276","Mecillinam for Treatment of Genital Chlamydia Infection",[91],"2015-05","2014-03",[5735,5736],"Chlamydia Trachomatis Infection","Chlamydial Urethritis",[5720],{"trials":5739,"activeCount":102},[],{"trials":5741,"activeCount":102},[],{"trials":5743,"activeCount":102},[],{"intervention":5745,"totalTrials":135,"cells":5746},"Vacc-4x low dose",{"EARLY_PHASE1":5747,"PHASE1":5749,"PHASE2":5751,"PHASE3":5765,"PHASE4":5767,"NA":5769},{"trials":5748,"activeCount":102},[],{"trials":5750,"activeCount":102},[],{"trials":5752,"activeCount":102},[5753],{"nctId":5754,"briefTitle":5755,"status":166,"phases":5756,"primaryCompletion":2091,"completion":2091,"start":5757,"enrollment":5758,"conditions":5759,"interventions":5761},"NCT01473810","Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant",[90,91],"2011-11",24,[5760],"HIV Infection",[5745,5762,5763,5764],"Vacc-4x medium dose","Vacc-4x high dose","Zero dose",{"trials":5766,"activeCount":102},[],{"trials":5768,"activeCount":102},[],{"trials":5770,"activeCount":102},[],{"intervention":5762,"totalTrials":135,"cells":5772},{"EARLY_PHASE1":5773,"PHASE1":5775,"PHASE2":5777,"PHASE3":5783,"PHASE4":5785,"NA":5787},{"trials":5774,"activeCount":102},[],{"trials":5776,"activeCount":102},[],{"trials":5778,"activeCount":102},[5779],{"nctId":5754,"briefTitle":5755,"status":166,"phases":5780,"primaryCompletion":2091,"completion":2091,"start":5757,"enrollment":5758,"conditions":5781,"interventions":5782},[90,91],[5760],[5745,5762,5763,5764],{"trials":5784,"activeCount":102},[],{"trials":5786,"activeCount":102},[],{"trials":5788,"activeCount":102},[],{"intervention":5763,"totalTrials":135,"cells":5790},{"EARLY_PHASE1":5791,"PHASE1":5793,"PHASE2":5795,"PHASE3":5801,"PHASE4":5803,"NA":5805},{"trials":5792,"activeCount":102},[],{"trials":5794,"activeCount":102},[],{"trials":5796,"activeCount":102},[5797],{"nctId":5754,"briefTitle":5755,"status":166,"phases":5798,"primaryCompletion":2091,"completion":2091,"start":5757,"enrollment":5758,"conditions":5799,"interventions":5800},[90,91],[5760],[5745,5762,5763,5764],{"trials":5802,"activeCount":102},[],{"trials":5804,"activeCount":102},[],{"trials":5806,"activeCount":102},[],{"intervention":5764,"totalTrials":135,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5810,"activeCount":102},[],{"trials":5812,"activeCount":102},[],{"trials":5814,"activeCount":102},[5815],{"nctId":5754,"briefTitle":5755,"status":166,"phases":5816,"primaryCompletion":2091,"completion":2091,"start":5757,"enrollment":5758,"conditions":5817,"interventions":5818},[90,91],[5760],[5745,5762,5763,5764],{"trials":5820,"activeCount":102},[],{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[],{"intervention":5826,"totalTrials":135,"cells":5827},"MOC31PE Immunotoxin",{"EARLY_PHASE1":5828,"PHASE1":5830,"PHASE2":5832,"PHASE3":5842,"PHASE4":5844,"NA":5846},{"trials":5829,"activeCount":102},[],{"trials":5831,"activeCount":102},[],{"trials":5833,"activeCount":102},[5834],{"nctId":5835,"briefTitle":5836,"status":166,"phases":5837,"primaryCompletion":5838,"completion":5838,"start":416,"enrollment":19,"conditions":5839,"interventions":5841},"NCT02219893","Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial",[90,91],"2016-12-10",[5840],"Colorectal Neoplasms",[5826],{"trials":5843,"activeCount":102},[],{"trials":5845,"activeCount":102},[],{"trials":5847,"activeCount":102},[],{"intervention":5849,"totalTrials":135,"cells":5850},"Allopurinol 300 mg",{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5852,"activeCount":102},[],{"trials":5854,"activeCount":102},[],{"trials":5856,"activeCount":102},[5857],{"nctId":5858,"briefTitle":5859,"status":166,"phases":5860,"primaryCompletion":5861,"completion":5861,"start":5862,"enrollment":5863,"conditions":5864,"interventions":5867},"NCT03353298","Lowering Uric Acid in Live Kidney Donors",[91],"2020-09-25","2018-01-17",71,[5865,5866],"Renal Transplant Donor of Left Kidney","Renal Transplant Donor of Right Kidney",[5849],{"trials":5869,"activeCount":102},[],{"trials":5871,"activeCount":102},[],{"trials":5873,"activeCount":102},[],{"intervention":5875,"totalTrials":135,"cells":5876},"Dendritic cell vaccine with mRNA from tumor stem cells",{"EARLY_PHASE1":5877,"PHASE1":5879,"PHASE2":5881,"PHASE3":5892,"PHASE4":5894,"NA":5896},{"trials":5878,"activeCount":102},[],{"trials":5880,"activeCount":102},[],{"trials":5882,"activeCount":102},[5883],{"nctId":5884,"briefTitle":5885,"status":166,"phases":5886,"primaryCompletion":5887,"completion":5887,"start":5888,"enrollment":373,"conditions":5889,"interventions":5891},"NCT00846456","Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma",[90,91],"2013-02","2009-01",[3795,5890],"Brain Tumor",[5875],{"trials":5893,"activeCount":102},[],{"trials":5895,"activeCount":102},[],{"trials":5897,"activeCount":102},[],{"intervention":5899,"totalTrials":135,"cells":5900},"Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg",{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5905,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5902,"activeCount":102},[],{"trials":5904,"activeCount":102},[],{"trials":5906,"activeCount":102},[5907],{"nctId":5908,"briefTitle":5909,"status":220,"phases":5910,"primaryCompletion":5911,"completion":5912,"start":5093,"enrollment":5913,"conditions":5914,"interventions":5918},"NCT04662866","Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose",[91],"2022-12","2023-10",64,[5915,5916,5917],"Impaired Glucose Tolerance","Insulin Sensitivity","Glucose Metabolism Disorders",[5899],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[],{"trials":5924,"activeCount":102},[],{"intervention":5926,"totalTrials":135,"cells":5927},"H7HLAII",{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5941,"PHASE3":5943,"PHASE4":5945,"NA":5947},{"trials":5929,"activeCount":102},[],{"trials":5931,"activeCount":102},[5932],{"nctId":5933,"briefTitle":5934,"status":220,"phases":5935,"primaryCompletion":5219,"completion":5219,"start":5936,"enrollment":1578,"conditions":5937,"interventions":5940},"NCT06046092","H7HLAII DNA Influenza Vaccine",[90],"2023-07-15",[5938,5939],"Influenza A","Pandemic Influenza",[5926],{"trials":5942,"activeCount":102},[],{"trials":5944,"activeCount":102},[],{"trials":5946,"activeCount":102},[],{"trials":5948,"activeCount":102},[],{"intervention":5950,"totalTrials":135,"cells":5951},"Vorinostat",{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5965,"PHASE3":5967,"PHASE4":5969,"NA":5971},{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[5956],{"nctId":5957,"briefTitle":5958,"status":166,"phases":5959,"primaryCompletion":3058,"completion":5960,"start":3861,"enrollment":19,"conditions":5961,"interventions":5964},"NCT00455351","Vorinostat and Palliative Radiotherapy",[90],"2009-08",[5962,5963],"Pelvic Cancer","Radiotherapy",[5950],{"trials":5966,"activeCount":102},[],{"trials":5968,"activeCount":102},[],{"trials":5970,"activeCount":102},[],{"trials":5972,"activeCount":102},[],{"intervention":5974,"totalTrials":135,"cells":5975},"MOC31-PE",{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5988,"PHASE3":5990,"PHASE4":5992,"NA":5994},{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[5980],{"nctId":5981,"briefTitle":5982,"status":166,"phases":5983,"primaryCompletion":5984,"completion":5984,"start":4519,"enrollment":373,"conditions":5985,"interventions":5987},"NCT01061645","Study of MOC31-PE in Antigen Positive Carcinomas",[90],"2012-02",[5986],"Carcinoma",[5974],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[],{"trials":5993,"activeCount":102},[],{"trials":5995,"activeCount":102},[],{"intervention":5997,"totalTrials":135,"cells":5998},"Oxygen gas",{"EARLY_PHASE1":5999,"PHASE1":6001,"PHASE2":6013,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6000,"activeCount":102},[],{"trials":6002,"activeCount":102},[6003],{"nctId":6004,"briefTitle":6005,"status":166,"phases":6006,"primaryCompletion":6007,"completion":6007,"start":6008,"enrollment":19,"conditions":6009,"interventions":6011},"NCT05150418","Supplemental Oxygen in Hypovolemia",[90],"2022-06-14","2021-11-26",[1868,6010],"Hyperoxia",[5997,6012],"Air",{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[],{"trials":6020,"activeCount":102},[],{"intervention":6012,"totalTrials":135,"cells":6022},{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6031,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[6027],{"nctId":6004,"briefTitle":6005,"status":166,"phases":6028,"primaryCompletion":6007,"completion":6007,"start":6008,"enrollment":19,"conditions":6029,"interventions":6030},[90],[1868,6010],[5997,6012],{"trials":6032,"activeCount":102},[],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[],{"trials":6038,"activeCount":102},[],{"intervention":6040,"totalTrials":135,"cells":6041},"Indocyanine green",{"EARLY_PHASE1":6042,"PHASE1":6054,"PHASE2":6056,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6043,"activeCount":102},[6044],{"nctId":6045,"briefTitle":6046,"status":220,"phases":6047,"primaryCompletion":6048,"completion":6048,"start":6049,"enrollment":404,"conditions":6050,"interventions":6053},"NCT01204554","Microcirculation in Perforator Flaps. Enhancing Tissue Survival",[89],"2010-12","2008-09",[6051,6052],"Reconstructive Surgery","Microcirculation",[6040],{"trials":6055,"activeCount":102},[],{"trials":6057,"activeCount":102},[],{"trials":6059,"activeCount":102},[],{"trials":6061,"activeCount":102},[],{"trials":6063,"activeCount":102},[],{"intervention":6065,"totalTrials":135,"cells":6066},"Personalized drug combination",{"EARLY_PHASE1":6067,"PHASE1":6079,"PHASE2":6081,"PHASE3":6083,"PHASE4":6085,"NA":6087},{"trials":6068,"activeCount":102},[6069],{"nctId":6070,"briefTitle":6071,"status":220,"phases":6072,"primaryCompletion":6073,"completion":6074,"start":6075,"enrollment":19,"conditions":6076,"interventions":6078},"NCT05043701","Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma",[89],"2024-12","2026-02","2023-03-01",[6077],"Recurrent Glioblastoma",[6065],{"trials":6080,"activeCount":102},[],{"trials":6082,"activeCount":102},[],{"trials":6084,"activeCount":102},[],{"trials":6086,"activeCount":102},[],{"trials":6088,"activeCount":102},[],{"intervention":6090,"totalTrials":135,"cells":6091},"Plasma exchenge",{"EARLY_PHASE1":6092,"PHASE1":6102,"PHASE2":6104,"PHASE3":6106,"PHASE4":6108,"NA":6110},{"trials":6093,"activeCount":102},[6094],{"nctId":6095,"briefTitle":6096,"status":220,"phases":6097,"primaryCompletion":5219,"completion":745,"start":6098,"enrollment":28,"conditions":6099,"interventions":6101},"NCT06234436","Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)",[89],"2023-12-07",[6100],"Alzheimer Disease",[6090],{"trials":6103,"activeCount":102},[],{"trials":6105,"activeCount":102},[],{"trials":6107,"activeCount":102},[],{"trials":6109,"activeCount":102},[],{"trials":6111,"activeCount":102},[],{"intervention":2683,"totalTrials":5684,"cells":6113},{"EARLY_PHASE1":6114,"PHASE1":6116,"PHASE2":6118,"PHASE3":6132,"PHASE4":6134,"NA":6140},{"trials":6115,"activeCount":102},[],{"trials":6117,"activeCount":102},[],{"trials":6119,"activeCount":102},[6120,6124],{"nctId":4465,"briefTitle":4466,"status":166,"phases":6121,"primaryCompletion":2032,"completion":4468,"start":2103,"enrollment":4469,"conditions":6122,"interventions":6123},[91],[4471,4472],[2683,4456],{"nctId":6125,"briefTitle":6126,"status":915,"phases":6127,"primaryCompletion":6128,"completion":6128,"start":6129,"enrollment":373,"conditions":6130,"interventions":6131},"NCT01956604","The Oslo Study of Clonidine in Elderly Patients With Delirium",[91],"2017-09-12","2014-04-10",[2679],[2683],{"trials":6133,"activeCount":102},[],{"trials":6135,"activeCount":102},[6136],{"nctId":2671,"briefTitle":2672,"status":220,"phases":6137,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":6138,"interventions":6139},[93],[2679,2680,2681],[2658,2683,2684],{"trials":6141,"activeCount":102},[6142],{"nctId":6143,"briefTitle":6144,"status":166,"phases":6145,"primaryCompletion":2477,"start":3101,"enrollment":1589,"conditions":6146,"interventions":6147},"NCT01507701","Pilot Study for the NorCAPITAL Trial",[94],[4471],[2683],{"intervention":6149,"totalTrials":135,"cells":6150},"GV 1001 Telomerase peptide",{"EARLY_PHASE1":6151,"PHASE1":6153,"PHASE2":6155,"PHASE3":6157,"PHASE4":6159,"NA":6161},{"trials":6152,"activeCount":102},[],{"trials":6154,"activeCount":102},[],{"trials":6156,"activeCount":102},[],{"trials":6158,"activeCount":102},[],{"trials":6160,"activeCount":102},[],{"trials":6162,"activeCount":102},[6163],{"nctId":6164,"briefTitle":6165,"status":166,"phases":6166,"completion":5960,"start":6167,"enrollment":373,"conditions":6168,"interventions":6170},"NCT00509457","GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)",[94],"2006-11",[6169],"Carcinoma, Non-Small-Cell Lung",[6149],{"intervention":6172,"totalTrials":135,"cells":6173},"Nicotine",{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6180,"PHASE4":6182,"NA":6184},{"trials":6175,"activeCount":102},[],{"trials":6177,"activeCount":102},[],{"trials":6179,"activeCount":102},[],{"trials":6181,"activeCount":102},[],{"trials":6183,"activeCount":102},[],{"trials":6185,"activeCount":102},[6186],{"nctId":6187,"briefTitle":6188,"status":166,"phases":6189,"primaryCompletion":1291,"completion":1291,"start":3005,"enrollment":4885,"conditions":6190,"interventions":6191},"NCT02350335","Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage",[94],[5476],[6172],{"intervention":6193,"totalTrials":135,"cells":6194},"Botulinum toxin",{"EARLY_PHASE1":6195,"PHASE1":6197,"PHASE2":6199,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6196,"activeCount":102},[],{"trials":6198,"activeCount":102},[],{"trials":6200,"activeCount":102},[],{"trials":6202,"activeCount":102},[],{"trials":6204,"activeCount":102},[],{"trials":6206,"activeCount":102},[6207],{"nctId":6208,"briefTitle":6209,"status":220,"phases":6210,"primaryCompletion":6211,"completion":5219,"start":6212,"enrollment":404,"conditions":6213,"interventions":6215},"NCT04432285","Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia",[],"2023-01-30","2020-08-06",[6214],"Cervical Dystonia",[6193],{"intervention":6217,"totalTrials":135,"cells":6218},"Spinal anaesthesia",{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6220,"activeCount":102},[],{"trials":6222,"activeCount":102},[],{"trials":6224,"activeCount":102},[],{"trials":6226,"activeCount":102},[],{"trials":6228,"activeCount":102},[],{"trials":6230,"activeCount":102},[6231],{"nctId":6232,"briefTitle":6233,"status":915,"phases":6234,"primaryCompletion":6235,"completion":6235,"start":6236,"enrollment":135,"conditions":6237,"interventions":6240},"NCT04819503","Mechanisms and Treatment of Post-amputation Neuropathic Pain",[94],"2021-12-03","2021-01-01",[1830,6238,6239],"Phantom Limb Pain","Amputation",[6217],{"intervention":6242,"totalTrials":135,"cells":6243},"HYPOCOL®",{"EARLY_PHASE1":6244,"PHASE1":6246,"PHASE2":6248,"PHASE3":6250,"PHASE4":6252,"NA":6254},{"trials":6245,"activeCount":102},[],{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[],{"trials":6253,"activeCount":102},[],{"trials":6255,"activeCount":102},[6256],{"nctId":6257,"briefTitle":6258,"status":166,"phases":6259,"primaryCompletion":6260,"completion":2832,"start":2925,"enrollment":115,"conditions":6261,"interventions":6263},"NCT00114855","The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose",[94],"2005-12",[6262,5917],"Hyperlipidemia",[6242],{"intervention":6265,"totalTrials":135,"cells":6266},"SARS-CoV-2 vaccine",{"EARLY_PHASE1":6267,"PHASE1":6269,"PHASE2":6271,"PHASE3":6273,"PHASE4":6275,"NA":6277},{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[],{"trials":6274,"activeCount":102},[],{"trials":6276,"activeCount":102},[],{"trials":6278,"activeCount":102},[6279],{"nctId":6280,"briefTitle":6281,"status":220,"phases":6282,"primaryCompletion":5219,"completion":5219,"start":6283,"enrollment":147,"conditions":6284,"interventions":6286},"NCT04747522","Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)",[],"2021-01-22",[6285,4224],"Kidney Transplant Infection",[6265],{"intervention":6288,"totalTrials":135,"cells":6289},"sildenafil citrate",{"EARLY_PHASE1":6290,"PHASE1":6292,"PHASE2":6294,"PHASE3":6296,"PHASE4":6298,"NA":6300},{"trials":6291,"activeCount":102},[],{"trials":6293,"activeCount":102},[],{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[],{"trials":6301,"activeCount":102},[6302],{"nctId":6303,"briefTitle":6304,"status":220,"phases":6305,"primaryCompletion":6306,"completion":5565,"start":6049,"enrollment":19,"conditions":6307,"interventions":6308},"NCT00772135","Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients",[94],"2009-02",[5047],[6288],{"intervention":6310,"totalTrials":135,"cells":6311},"Standard Chemotherapy",{"EARLY_PHASE1":6312,"PHASE1":6314,"PHASE2":6316,"PHASE3":6318,"PHASE4":6320,"NA":6322},{"trials":6313,"activeCount":102},[],{"trials":6315,"activeCount":102},[],{"trials":6317,"activeCount":102},[],{"trials":6319,"activeCount":102},[],{"trials":6321,"activeCount":102},[],{"trials":6323,"activeCount":102},[6324],{"nctId":6325,"briefTitle":6326,"status":915,"phases":6327,"primaryCompletion":6328,"completion":6328,"start":6329,"enrollment":733,"conditions":6330,"interventions":6332},"NCT01867918","LOTCOL Study: Local Treatment of Colo-rectal Liver Met",[94],"2016-12","2013-05",[6331],"Metastatic Colo-rectal Cancer",[6310],{"intervention":6334,"totalTrials":135,"cells":6335},"Vitamin K",{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6340,"PHASE3":6342,"PHASE4":6344,"NA":6346},{"trials":6337,"activeCount":102},[],{"trials":6339,"activeCount":102},[],{"trials":6341,"activeCount":102},[],{"trials":6343,"activeCount":102},[],{"trials":6345,"activeCount":102},[],{"trials":6347,"activeCount":102},[6348],{"nctId":6349,"briefTitle":6350,"status":220,"phases":6351,"primaryCompletion":3185,"completion":2092,"start":6352,"enrollment":6353,"conditions":6354,"interventions":6357},"NCT00826254","Nutritional Problems After Lung and Heart Transplantation",[94],"2003-08",94,[6355,6356],"Bone Density","Overweight",[6334,6334],{"intervention":6359,"totalTrials":135,"cells":6360},"Praziquantel",{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6367,"PHASE4":6369,"NA":6371},{"trials":6362,"activeCount":102},[],{"trials":6364,"activeCount":102},[],{"trials":6366,"activeCount":102},[],{"trials":6368,"activeCount":102},[],{"trials":6370,"activeCount":102},[],{"trials":6372,"activeCount":102},[6373],{"nctId":6374,"briefTitle":6375,"status":220,"phases":6376,"primaryCompletion":41,"completion":6377,"start":6378,"enrollment":6379,"conditions":6380,"interventions":6382},"NCT01154907","Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa",[],"2021-12","2010-04",6500,[6381],"Uro-genital Schistosomiasis",[6359],{"intervention":6384,"totalTrials":135,"cells":6385},"Pikasol",{"EARLY_PHASE1":6386,"PHASE1":6388,"PHASE2":6390,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6387,"activeCount":102},[],{"trials":6389,"activeCount":102},[],{"trials":6391,"activeCount":102},[],{"trials":6393,"activeCount":102},[],{"trials":6395,"activeCount":102},[],{"trials":6397,"activeCount":102},[6398],{"nctId":6399,"briefTitle":6400,"status":166,"phases":6401,"primaryCompletion":6402,"completion":6402,"start":4468,"enrollment":6403,"conditions":6404,"interventions":6406},"NCT01841944","Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction",[94],"2020-06-26",1027,[2835,2836,6405,36],"Myocardial Revascularization",[6384],{"intervention":6408,"totalTrials":135,"cells":6409},"analgesic drugs and methods",{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6414,"PHASE3":6416,"PHASE4":6418,"NA":6420},{"trials":6411,"activeCount":102},[],{"trials":6413,"activeCount":102},[],{"trials":6415,"activeCount":102},[],{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[6422],{"nctId":6423,"briefTitle":6424,"status":220,"phases":6425,"primaryCompletion":6426,"completion":6427,"start":1827,"enrollment":115,"conditions":6428,"interventions":6431},"NCT03730272","Occurence of Pain and Use of Analgesic Treatment in Multi-trauma Patients of Intermediate Seveity",[],"2019-03","2019-11-01",[6429,6430],"Post Traumatic Pain","Post Traumatic Analgesic Treatment",[6408],{"intervention":6433,"totalTrials":135,"cells":6434},"Infliximab, adalimumab, certolizumab pegol",{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6441,"PHASE4":6443,"NA":6445},{"trials":6436,"activeCount":102},[],{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":102},[],{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[],{"trials":6446,"activeCount":102},[6447],{"nctId":6448,"briefTitle":6449,"status":166,"phases":6450,"primaryCompletion":6451,"completion":6452,"start":6329,"enrollment":6453,"conditions":6454,"interventions":6458},"NCT02073526","Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease",[],"2016-05","2016-11",1230,[6455,6456,6457],"Inflammatory Bowel Disease","Crohn's Disease","Ulcerative Colitis",[6433],{"intervention":6460,"totalTrials":135,"cells":6461},"Ipilimumab, nivolumab or pembrolizumab",{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6463,"activeCount":102},[],{"trials":6465,"activeCount":102},[],{"trials":6467,"activeCount":102},[],{"trials":6469,"activeCount":102},[],{"trials":6471,"activeCount":102},[],{"trials":6473,"activeCount":102},[6474],{"nctId":6475,"briefTitle":6476,"status":220,"phases":6477,"primaryCompletion":6478,"completion":5219,"start":6479,"enrollment":4885,"conditions":6480,"interventions":6482},"NCT03458455","Improved Therapy Response Assessment in Metastatic Brain Tumors",[],"2024-07-31","2013-03-01",[6481],"Brain Metastases",[6460],{"intervention":6484,"totalTrials":135,"cells":6485},"Triamcinolone hexacetonide",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6490,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6487,"activeCount":102},[],{"trials":6489,"activeCount":102},[],{"trials":6491,"activeCount":102},[],{"trials":6493,"activeCount":102},[],{"trials":6495,"activeCount":102},[],{"trials":6497,"activeCount":102},[6498],{"nctId":6499,"briefTitle":6500,"status":166,"phases":6501,"primaryCompletion":2032,"completion":2032,"start":6306,"enrollment":6502,"conditions":6503,"interventions":6505},"NCT00840229","Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder",[94],122,[6504],"Adhesive Capsulitis",[6484,6484]]